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ABSTRACT	  The	   F-­‐box	   protein	   FBW7	   is	   a	   tumor	   suppressor	   and	   SCF	   ubiquitin	   ligase	   targeting	  several	   key	   oncoproteins	   for	   proteasomal	   degradation.	   In	   this	   thesis	   we	   addressed	  whether	  the	  FBW7	  gene	  is	  inactivated	  by	  mutations	  in	  various	  human	  tumor	  types	  and	  explored	  alternative	  mechanism(s)	  for	  the	  inactivation	  of	  FBW7.	  We	  also	  explored	  how	  inactivation	  of	  FBW7	  relates	  to	  substrate	  degradation	  (including	  cyclin	  E,	  Notch1	  and	  c-­‐Myc)	  and	  its	  potential	  prognostic	  significance.	  Furthermore,	  we	  have	  investigated	  novel	  regulatory	  mechanism(s)	  for	  FBW7	  expression	  and	  activity.	  	  	  Our	  results	  demonstrate	  that	  FBW7	  is	  a	  general	  TSG,	  which	  is	  frequently	  inactivated	  by	  mutations	   (with	   an	   average	   mutation	   frequency	   of	   6%)	   in	   various	   malignancies.	  Heterozygous	   missense	   mutations	   altering	   specific	   arginines	   residues	   required	   for	  efficient	  substrate	  interaction	  are	  the	  most	  frequent	  mutations	  in	  FBW7.	  Our	  functional	  analysis	   indicates	   that	   heterozygous	   mutations	   might	   act	   in	   a	   dominant-­‐negative	  manner.	   The	   highest	   mutation	   frequency	   was	   observed	   in	   cholangiocarcinomas	   and	  pediatric	  T-­‐cell	  acute	  lymphocytic	  leukemias	  (T-­‐ALL)	  (35	  and	  31	  %,	  respectively).	  We	  also	   found	   that	  FBW7	  gene	  mutation	   is	   an	   infrequent	   event	   in	   several	  malignancies,	  including	  breast	   cancer	  and	  pediatric	  B-­‐ALL.	  This	   finding	  prompted	  us	   to	   investigate	  whether	   alternative	   mechanism	   for	   regulation	   and	   inactivation	   of	   FBW7	   occurs	   in	  cancer,	   including	   promoter	   hypermethylation	   and	   miRNA	   induced	   repression.	   Our	  results	   demonstrate	   that	   both	   the	   5’-­‐UTR	   and	   the	   3’-­‐UTR	   of	   FBW7	   is	   epigenetically	  regulated.	   The	   promoter	   of	   FBW7-­beta	   is	   frequently	   hypermethylated	   in	   primary	  breast	   tumors	   and	   its	   inactivation	   is	   associated	   with	   improved	   survival	   in	   certain	  patient	  subgroups.	  Similarly,	  mutational	  inactivation	  of	  FBW7	  and/or	  NOTCH1	  in	  T-­‐ALL	  is	   also	   associated	  with	   increased	   overall	   survival.	   Analyses	   focusing	   on	   the	   3’UTR	   of	  
FBW7	   revealed	   that	   FBW7	  expression	   is	   regulated	  by	  miR-­‐27a,	   a	   putative	   oncogenic	  miRNA.	  miR-­‐27a	  was	  identified	  as	  a	  critical	  repressor	  of	  FBW7	  expression	  during	  cell	  cycle	  progression	  with	  potential	  consequences	   for	  FBW7-­‐mediated	  turnover	  of	  cyclin	  E.	   These	   results	   indicate	   that	   miR-­‐27a	   serves	   an	   important	   cell	   cycle	   regulatory	  function	   by	   repressing	   FBW7	   and	   at	   specific	   cell	   cycle	   stages,	   but	   releasing	   it	   from	  repression	  during	  the	  G1	  to	  S-­‐phase	  transition.	  	  	  In	   summary,	   our	   findings	   demonstrate	   that	  FBW7	   is	   inactivated	   by	   several	   different	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mechanisms,	  including	  mutation,	  deletion,	  promoter	  methylation	  and	  possibly	  miRNA-­‐induced	  repression	  of	  gene	  expression.	  Our	  pre-­‐clinical	  analysis	   further	  suggests	   that	  inactivation	   of	   FBW7	   in	   certain	   malignancies	   might	   be	   associated	   with	   improved	  survival,	  thus	  implicating	  FBW7	  as	  a	  potential	  prognostic	  predictor	  in	  the	  some	  cancers.	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1 LIST OF ABBREVIATIONS Ago	   argonaute	  AMFR	  APC	   anaphase-­‐promoting	  complex	  ATM	   ataxia	  telangiectasia	  mutated	  ATR	   ataxia	  telangiectasia	  and	  Rad3	  related	  B-­‐ALL	   B-­‐cell	  Acute	  Lymphoblastic	  Leukemia	  BRCA	   breast	  cancer	  bTRCP	   Beta	  Transducin	  Repeat	  Containing	  Protein	  Cdk	   Cyclin-­‐dependent	  kinase	  CPD	  	   Cdc4	  phosphodegron	  CRL	   Cullin-­‐RING	  E3	  ubiquitin-­‐Ligase	  CSL	   CBF1	  Suppressor	  of	  Hairless-­‐Lag1	  CSN	   COP9	  signalosome	  Cul1	   cullin1	  DD	   dimerization	  domain	  DNA	   deoxyribonucleic	  acid	  DUB	   deubiquitylating	  enzyme	  E6AP	   E6-­‐associated	  protein	  ER	   endoplasmic	  reticulum	  ERK	   extracellular	  signal-­‐regulated	  kinases	  Far1	   fatty	  acyl	  CoA	  reductase	  1	  FBXW7	   F-­‐box	  and	  WD-­‐40	  domain	  protein	  7	  GSK	   glycogen	  synthase	  kinase	  hCdc4	   human	  cell	  division	  cycle	  4	  HECT	   	   homologous	  to	  the	  E6-­‐AP	  carboxyl	  terminus	  ICD	   intracellular	  domain	  LOH	   loss	  of	  heterozygosity	  LRR	   Leucine	  rich	  repeat	  MAM	   mastermind-­‐like	  MCL1	   myeloid	  cell	  leukemia	  sequence	  1	  Mdm2	   mouse	  double	  minute	  2	  miRNA	   microRNA	  mRNA	   messenger	  RNA	  Myc	   myelocytomatosis	  NICD	   Notch	  intracellular	  domain	  ORC	   origin	  of	  replication	  complex	  PARP	   Poly	  ADP-­‐ribose	  polymerase	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PEST	   proline	  (P),	  glutamic	  acid	  (E),	  serine	  (S),	  and	  threonine	  (T)	  PI3K	   Phosphatidylinositol	  3-­‐kinases	  Pop1,	  2	   processing	  of	  precursor	  1,	  2	  PP2A	   protein	  phosphatase	  2	  A	  PTEN	   phosphatase	  and	  tensin	  homolog	  RAS	   rat	  sarcoma	  viral	  oncogene	  homolog	  RING	   really	  interesting	  new	  gene	  RNA	   ribonucleic	  acid	  RNAi	   RNA	  interference	  SCF	   Skp1/Cul1/F-­‐box	  Ser	   serine	  Sic1	   stoichiometric	  inhibitor	  of	  Cdk1-­‐Clb	  Skp1	   S-­‐phase	  kinase-­‐associated	  protein	  1	  Skp2	   S-­‐phase	  kinase-­‐associated	  protein	  2	  T-­‐ALL	   T-­‐cell	  Acute	  Lymphoblastic	  Leukemia	  TGF	   transforming	  growth	  factor	  Thr	   threonine	  TM	   transmembrane	  TP53	   tumor	  protein	  p53	  TSG	   Tumor	  suppressor	  gene	  Ub	   ubiquitin	  Ubc	   ubiquitin	  conjugating	  enzyme	  UBD	   ubiquitin	  binding	  domain	  UPS	   ubiquitin	  proteasome	  system	  USP28	   ubiquitin	  specific	  peptidase	  28	  UTR	   untranslated	  region	  WNT	   wingless	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2 INTRODUCTION	  	  This	  thesis	  touches	  upon	  various	  concepts	   in	  cell	  biology	  including	  tumor	  suppressor	  genes,	   oncogenes,	   gene	   regulatory	   mechanisms	   such	   as	   DNA	   methylation	   and	  microRNA	   expression,	   phosphorylation,	   ubiquitylation	   and	   some	   other	   aspects	   of	  processes	  that	  are	  dysregulated	   in	  cancer.	  The	  reason	   is	   that	  FBW7,	  a	  gene	  originally	  shown	   to	   be	   a	   tumor	   suppressor	   through	   its	   negative	   effect	   on	   proteins	   promoting	  proliferation,	   is	   now	   known	   to	   be	   a	  multifunctional	   gene	   involved	   in	  many	   different	  biological	  processes.	  Since	  it	  became	  apparent	  that	  FBW7	  is	  a	  master	  regulator	  of	  many	  well-­‐known	  oncoproteins,	  it	  was	  important	  to	  determine	  how	  it	  may	  be	  regulated	  and	  how	   it	   is	   functionally	   inactivated	   in	   tumors.	   	  The	  studies	   in	   this	   thesis	   show	  that	   the	  FBW7gene	   is	   in	   fact	   inactivated	   via	   various	  mechanisms	   in	   different	   human	   tumors.	  Although	   is	   not	   fully	   understood	   how	  FBW7	   gene	   inactivation	   contributes	   to	   cancer	  development	  and	  progression,	  it	  is	  the	  beginning	  of	  the	  way	  that	  will	  eventually	  lead	  to	  better	  understanding	  of	  the	  role	  of	  FBW7	  in	  tumorigenesis	  and	  treatment	  of	  cancer.	  	  	  	  
2.1 CANCER	  
	  	  
2.1.1 History of cancer  The	  oldest	  documented	  case	  of	  cancer	  was	  recorded	  on	  a	  papyrus	  from	  ancient	  Egypt,	  in	   1500	   b.c.	   However,	   Hippocrates,	   the	   great	  Greek	  physician	   (460-­‐370	  B.C),	  who	   is	  referred	   to	   as	   the	   father	   of	   medicine	   is	   thought	   to	   be	   the	   first	   person	   who	   named	  ¨cancer¨.	   Hippocrates	   used	   the	   name	   karkinos	   (the	   Greek	   name	   for	   crab,	   in	   English	  carcinos	   or	   carcinomas)	   to	   describe	   a	   skin	  wound	   that	   he	   thought	   of	   as	   a	   particular	  disease.	   His	   writings	   contain	   detailed	   descriptions	   of	   different	   types	   of	   cancers	  involving	  various	  sites	  in	  the	  body	  [1].	  	  	  
2.1.2 Development of cancer In	   ancient	   Egypt,	   it	  was	   believed	   that	   cancer	  was	   caused	   by	   the	   Gods.	   Hippocrates	  believed	  that	  an	  excess	  of	  black	  bile	  in	  any	  given	  site	  in	  the	  body	  caused	  cancer	  and	  it	  was	  also	  the	  general	  thought	  for	  the	  cause	  of	  cancer	  in	  the	  next	  1400	  years.	  Despite	  stunning	   progress	   in	   our	   understanding	   of	   the	   cells	   that	   build	   up	   the	   human	   body	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  Figure	  1.	  Hallmarks	  of	  cancer	  	  Globally,	   there	   are	   approximately	   7.4	   million	   cancer	   deaths	   annually.	   Cancer	   is	   a	  leading	   cause	   of	   death	  worldwide	   and	   it	   accounts	   for	   approximately	   13%	   of	   deaths	  from	  all	  causes.	  Encouragingly,	  during	  recent	  years,	  cancer	  mortality	  has	  stabilized	  in	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many	   countries.	   Part	   of	   this	   success	   may	   be	   attributed	   to	   the	   development	   of	   new	  cancer	  agents,	  collectively	  called	  ‘targeted	  therapies’	  [4,	  5].	  	  
2.1.3 Oncogenes  The	   discovery	   of	   the	   double	   helical	   DNA	   structure	   in	   1953	   by	   James	   Watson	   and	  Francis	   Crick	   was	   a	   revolution	   in	   biology	   since	   it	   explained	   DNA’s	   potential	   for	  replication	   and	   information	   encoding	   [6].	   Simultaneous	   development	   of	   techniques	  such	  as	  DNA	  hybridization	  suddenly	  enabled	  scientists	  to	  address	  many	  key	  issues	  in	  cancer	  biology.	  Although	  foreboded	  by	  earlier	  studies	  such	  as	  those	  of	  chromosome	  abnormalities,	  hereditary	  cancer	  and	  the	  involvement	  of	  mutagens	  in	  tumorigenesis,	  modern	   molecular	   biology	   enabled	   scientists	   to	   define	   the	   involvement	   of	   specific	  mutations	   in	   cancer	   development.	   This	   led	   to	   the	   breakthroughs	   in	   the	   1970s	   and	  early	   80s,	   when	   oncogenes	   and	   tumor	   suppressor	   genes	   were	   discovered.	   An	  oncogene	   is	   a	   gene	   that	  when	  mutated	   into	   an	   activated	   form	   has	   the	   potential	   to	  cause	  cancer.	  Oncogenes	  encode	  proteins	  that	  are	  involved	  in	  processes	  such	  as	  cell	  proliferation	   and	   apoptosis	   [7].	   The	  products	   of	   oncogenes	   act	   at	  multiple	   levels	   in	  the	   cell	   and	   can	   be	   transcription	   factors	   [8],	   chromatin	   remodelers	   [9-­‐11],	   growth	  factors	   [12],	   growth	   factor	   receptors	   [13],	   signal	   transducers	   [14]	   and	   apoptosis	  regulators	  [15,	  16].	  	  	  
2.1.3.1  Mechanisms of activation A	   proto-­‐oncogene	   is	   a	   normal	   gene	   converted	   into	   an	   oncogene	   if	   altered	   and	  activated.	  The	  resultant	  protein	  is	  called	  oncoprotein	  [17,	  18].	  Activation	  mechanisms	  of	   oncogenes	   can	   be	   categorized	   into	   three	   main	   classes:	   1)	   Chromosomal	  rearrangements,	  2)	  Mutations	  and	  3)	  Gene	  amplification,	  all	  of	  which	  confer	  a	  growth	  advantage	   or	   increased	   survival	   of	   cells	   carrying	   such	   alterations	   [19].	   All	   three	  mechanisms	   cause	   either	   structural	   alterations	   or	   an	   increased,	   deregulated	  expression	   of	   the	   oncoprotein	   [7,	   20].	   Examples	   of	   proto-­‐oncogenes	   frequently	  dysregulated	   in	   cancer	   development	   are	   RAS,	   WNT	   and	   MYC.	   The	   expression	   of	  oncogenes	  can	  also	  be	  dysregulated	  by	  other	  processes	  such	  as	  epi-­‐genetic	  alterations	  as	  well	   as	  microRNAs	   (miRNAs).	   The	   latter	   are	   a	   newly	   discovered	   group	   of	   small	  regulatory	  RNAs,	  that	  control	  gene	  expression	  through	  either	  translational	  repression	  or	   mRNA	   degradation	   [21].	   Dysregulation	   of	   such	   miRNAs	   can	   thus	   lead	   to	   the	  subsequent	  activation	  of	  the	  oncogene	  [22].	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2.1.4 Tumor suppressor genes  The	  discovery	  of	  proto-­‐oncogenes	  and	  oncogenes	  provided	  a	  powerful	  explanation	  of	  how	   the	   growth	   and	   proliferation	   of	   cells	   is	   positively	   regulated.	   Accepting	   the	  assumption	  that	  biological	  systems	  are	  balanced	  indicated	  that	  there	  could	  be	  genes	  that	  counteract	  proto-­‐oncogenes	  and	  prevent	  cells	  from	  uncontrolled	  growth.	  It	  was	  in	   the	  1970s	  and	  early	  1980s	  a	  second,	  and	   fundamentally	  different	   type	  of	  growth	  regulating	   genes	   began	   to	   accumulate	   [23].	   These	   genes	   were	   named	   ”Tumor	  suppressor	   genes“	   (TSGs)	   and	   possess	   anti-­‐proliferative	   properties	   [23].	   TSGs	   are	  defined	  as	  recessive	  genes	  that	  must	  sustain	  mutations	  or	  deletions	  of	  both	  alleles	  in	  order	   to	   contribute	   to	   cancer	   formation.	   This	   definition	  was	   described	  by	  Knudson	  and	  it	  known	  as	  Knudson’s	  'two-­‐hit'	  rule	  [24].	  It	  was	  later	  shown	  that	  some	  TSGs	  are	  exceptions	   to	   the	   Knudson’s	   'two-­‐hit'	   rule,	   referred	   to	   as	   haploinsufficient	   TSGs.	  Those	  genes	  contribute	  to	  tumor	  development	  even	  in	  the	  presence	  of	  one	  functional	  allele	   [25].	   The	   functions	   of	   tumor-­‐suppressor	   proteins	   are	   diverse	   but	   can	   be	  classified	  into	  different	  categories,	  including	  cell	  cycle	  regulation	  (e.g	  pRb,	  p27,	  p53),	  DNA	  damage	  (e.g	  ATM,	  ATR)	  and	  repair	  (i.e	  BRCA1,	  BRCA2),	  apoptosis	  (e.g	  p53,	  BAX),	  migration	  and	  invasion	  (e.g	  DLC1,	  PTEN),	  senescence	  (e.g	  p16,	  p19)	  [26-­‐33].	  	  	  
2.1.4.1 Mechanisms of inactivation Haploinsufficient	  TSGs	  may	  become	  inactivated	  following	  deletion	  or	  mutation	  of	  one	  single	  allele.	  However,	  since	  TSGs	  are	  often	  recessive,	  cells	  that	  contain	  one	  functional	  and	   one	   mutated	   gene	   (heterozygous)	   still	   behave	   normally.	   There	   are	   several	  mechanisms	  by	  which	  the	  normal	  allele	  may	  then	  become	  inactivated,	  which	  in	  turn	  can	   predispose	   a	   cell	   to	   cancer	   development.	   Among	   these	   mechanisms	   are	   large	  homozygous	  deletions	  or	  duplication	  of	  the	  mutated	  chromosome	  and	  complete	  loss	  of	  the	  normal	  counterpart,	  leading	  to	  so	  called	  Loss	  of	  Heterozygozity	  (LOH),	  as	  well	  as	   small	   deletions,	   point	   mutations,	   insertions,	   promoter	   hypermethylation	   and	  dominant	  negative	  effects	  [34,	  35].	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2.2 UBIQUITIN PROTEASOME SYSTEM (UPS) 
 
2.2.1 Background/history A	   requirement	   for	   normal	   cellular	   homeostasis	   [36,	   37]	   is	   that	   proteins	   are	  continuously	   synthesized	   and	  degraded	   inside	   our	   cells.	   This	  was	   first	   postulated	  by	  Schönheimer	   in	   1942	   in	   his	   book	   ¨The	   dynamic	   State	   of	   Body	   Constituents	   [38].	  Proteins	  that	  have	  served	  their	  functions	  and	  are	  no	  longer	  needed	  have	  to	  be	  removed.	  Additionally,	  misfolded	  or	  damaged	  proteins	  also	  need	  to	  be	  rapidly	  eliminated	  which	  could	   otherwise	   cause	   various	   kinds	   of	   problems	   to	   the	   cell	   [39].	   For	   a	   long	   time,	  proteins	  were	  thought	   to	  be	  degraded	   in	   lysosomes	  [40],	  and	   it	   took	  several	  decades	  before	   the	   pioneering	   work	   by	   Ciechanover,	   Hershko	   and	   Rose	   resulted	   in	   the	  discovery	   of	   a	   regulated	   energy-­‐dependent	   protein	   degradation	   process	   which	   is	  catalyzed	   by	   specific	   enzymatic	   activities	   and	   a	   small	   ubiquitous	   protein	   named	  ubiquitin	  (Ub)	  [40].	  This	  discovery	  was	  awarded	  the	  Nobel	  Prize	  in	  chemistry	  in	  2004	  [41].	   Ubiquitylation	   is	   the	   covalent	   attachment	   of	   ubiquitin	   to	   one	   or	   more	   lysine	  residues	  on	  a	  substrate	  protein	  and	  involves	  a	  cascade	  of	  key	  enzymatic	  activities:	  1)	  a	  ubiquitin-­‐activating	   enzyme	   (E1),	   that	   activates	   ubiquitin	   in	   an	   ATP	   dependent	  manner;	  2)	   a	   ubiquitin-­‐conjugating	   enzyme	   (E2);	   and	  3)	   a	   ubiquitin-­‐ligase	   (E3),	   that	  transfers	   the	   ubiquitin	   to	   specific	   lysine	   residues	   on	   target	   substrates	   (Figure	   2).	  Ubiquitylated	   substrates	   are	   then	   recognized	   by	   a	   large	   multi-­‐subunit	   protease	  complex,	  which	  is	  named	  the	  26S	  proteasome	  complex	  [42,	  43].	  Thus,	  the	  UPS	  can	  be	  divided	  into	  two	  distinct	  steps:	  ubiquitylation	  and	  proteasomal	  degradation	  (Figure	  2).	  Importantly,	  ubiquitin	  contain	  seven	  lysines,	  which	  all	  serve	  as	  potential	  acceptor	  sites	  for	  another	  ubiquitin	  molecule	  and	  can	  therefore	  result	  in	  different	  ubiquitin	  chains	  on	  substrates	   [40].	   In	   fact,	   the	   attachment	   of	   different	   types	   of	   ubiquitin	   chains	   on	  substrates	  can	  take	  several	  forms,	  each	  with	  potentially	  different	  biological	  outcomes.	  For	   example,	   attachment	   of	   a	   single	   ubiquitin	   (monoubiquitylation)	   often	   activates	  transcription	   factors,	   regulates	   protein	   trafficking,	   or	   targets	   proteins	   to	   the	  secretory/endocytic	  pathway	  [44].	  Attachment	  of	  a	  chain	  of	  lysine-­‐48	  linked	  ubiquitins	  (also	  called	  poly-­‐ubiquitylation)	  usually	  targets	  the	  substrate	  to	  the	  26S	  proteasome	  for	  ubiquitin-­‐mediated	  proteolysis	  [43]	  (Figure	  2).	  However,	  other	  types	  of	  polyubiquitin	  chains	   (e.g	   lysine-­‐63)	   can	   exert	   nonproteolytic	   functions,	   including	   kinase	   and	  transcription	   factor	   activation	   and	   chromatin	   remodelling	   [45].	   In	   addition,	   many	  proteins	   contain	   so-­‐called	   ubiquitin-­‐binding	   domains	   (UBDs)	   [46,	   47]	   enabling	   an	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additional	   level	   of	   regulation	   and	   translation	   of	   ubiquitin	  modifications	   into	   diverse	  cellular	   outputs,	   similar	   to	   protein	   phosphorylation.	   Finally,	   ubiquitylation	   is	  counteracted	  by	  deubiquitylating	  enzymes	  (DUBs)	  highlighting	  the	  reversibility	  of	  this	  enzymatic	  system	  [40].	  Given	  the	  critical	  function	  of	  an	  intact	  UPS,	  altered	  degradation	  of	  cellular	  regulators	  directly	  contributes	  to	  the	  development	  of	  hallmarks	  of	  cancer.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	   Figure	  2.	  Ubiquitin	  Proteasome	  System	  (UPS)	  	  


























domains	  (e.g	  WD40	  repeats).	  However,	  for	  a	  substrate	  to	  be	  recognized	  by	  an	  E3	  ligase	  it	   generally	   first	   has	   to	   be	   post-­‐translationally	   modified,	   for	   example	   by	  phosphorylation	  or	  proteolytic	  cleavage	  [48].	  The	  modified	  motif	   in	  the	  substrate	  has	  been	   termed	   degron	   [51].	   There	   are	   many	   different	   types	   of	   degrons	   (e.g	  phosphodegron,	  PEST).	  Once	  modified,	  a	  degron	  in	  a	  substrate	  might	  be	  recognized	  by	  a	  specific	  E3	  ligase,	  which	  forms	  the	  basis	  for	  its	  subsequent	  ubiquitylation.	  	  	  
2.2.3 SCF ubiquitin ligases and Cancer An	   important	   family	   of	   multimeric	   E3s	   is	   known	   as	   SCF	   (Figure	   3).	   SCF	   ligases	   are	  composed	   of	   an	   invariant	   core	   ligase	   comprised	   of	   the	   adaptor	   protein	   Skp1,	   the	  scaffold	  protein	  Cullin1	  and	  the	  RING	  domain	  protein	  Rbx1	  (also	  called	  Roc1	  or	  Hrt1),	  which	   recruits	   the	   E2	   enzyme	   Cdc34	   (also	   known	   as	   UBCH3)	   and	   one	   variable	  component	   called	   the	   F-­‐box	   protein.	   It	   is	   the	   F-­‐box	   protein	   that	   provides	   substrate	  specificity,	   usually	   through	   its	   C-­‐terminal	   protein-­‐protein	   interacting	   domains	   (often	  containing	  WD	  40	  and	  LRR	  repeats).	  The	  F-­‐box	  protein	  associates	  with	   the	  SCF	   core	  through	  binding	  to	  the	  adaptor	  protein	  Skp1,	  via	  its	  conserved	  F-­‐box	  domain	  (Figure	  3)	  [52,	  53].	  The	  F-­‐box	  is	  a	  protein	  domain	  of	  approximately	  40-­‐50	  amino	  acids	  in	  length.	  It	  was	  first	  identified	  in	  cyclin	  F,	  as	  its	  name	  implies	  [52].	  In	  the	  human	  genome,	  there	  are	  about	  70	  genes	  with	  F-­‐box	  domains,	  each	  likely	  targeting	  a	  unique	  set	  of	  substrates	  for	  degradation	   [54].	   Notably,	   a	   majority	   of	   the	   F-­‐box	   proteins	   are	   still	   completely	  uncharactierzed	  [55].	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	   	   	   	   	  	  	  	  Figure	  3.	  SCF	  ligase	  
	  A	  wealth	  of	  evidence	  suggests	  that	  SCF	  ligases	  play	  importnant	  roles	  in	  the	  control	  of	  cell	  division,	  which	  is	  almost	  a	  hallmark	  itself	  for	  this	  category	  of	  genes	  [Pagano].	  Not	  surprisingly,	   several	   F-­‐box	   proteins	   have	   been	   directly	   linked	   to	   tumorigenesis	   [56]	  
  15 





FBW7	   (also	   known	   as	   FBXW7,	   FBW7	   or	   hCDC4	   in	   humans,	   Cdc4	   in	   Saccharomyces	  cerevisiae,	  Sel-­10	  in	  Caenorhabditis	  elegans,	  or	  Ago	  in	  Drosophila	  melanogaster),	  is	  a	  substrate	   specificity	   factor	   for	   the	  SCF	  ubiquitin	   ligase	  SCFFBW7[58].	  FBW7	  was	   first	  identified	  in	  a	  genetic	  screen	  for	  cell	  division	  cycle	  (Cdc)	  mutants	  in	  S.	  cerevisiae	  [59]	  and	   was	   later	   implicated	   in	   the	   ubiquitin-­‐dependent	   proteolysis	   of	   the	   cyclin-­‐dependent	   kinase	   (Cdk)	   inhibitors	   Sic1	   and	   Far1	   [60],	   among	   others.	   In	  mammals,	  FBW7	  also	  regulates	  cell	  cycle	  progression	  and	  development	  through	  the	  degradation	  of	   specific	   transcription	   factors	   and	   cyclins	   [48,	   61]	   (see	   below).	   Thus,	   FBW7	   is	   a	  master	   regulator	   of	   cellular	   proliferation	   with	   important	   implications	   for	   several	  pathways	  regulating	  differentiation	  and	  development.	  	  
2.3.2 Gene/transcript/protein 
	  In	   humans,	   the	   FBW7	   gene	   spans	   over	   200	   kb	   on	   the	   long	   arm	   of	   chromosome	   4	  (4q31).	   It	   contains	  13	   exons	   and	   is	   alternatively	   spliced	   into	   three	   transcripts	  with	  unique	   5’-­‐exons	   termed	   alpha,	   beta	   and	   gamma	   [61]	   [62].	   The	   5’-­‐exon	   of	   each	  transcript	  is	  linked	  directly	  linked	  to	  exon	  2	  and	  each	  mRNA	  thus	  share	  all	  C-­‐terminal	  exons	   (exon	   2-­‐11)	   (Figure	   4).	   Importantly,	   the	   individual	   5’	   exons	   are	   coding	   and	  therefore	  generate	  three	  distinct	  protein	   isoforms	  that	  differ	  only	  at	  their	  N	  termini	  [63].	  This	  genomic	  organization	  is	  highly	  conserved	  in	  mammals	  and	  also	  allows	  for	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isoform-­‐specific	   transcriptional	  regulation,	  as	  each	  FBW7	   isoform	  is	  expressed	  from	  its	   own	   promoter	   [63].	   The	   FBW7	   protein	   contains	   several	   protein-­‐protein	  interaction	  domains	  (Figure	  4).	  The	  F-­‐box	  domain	  that	  recruits	  the	  SCF	  core	  complex	  through	   interaction	  with	  SKP1	  protein	   [52]	   is	   localized	   in	   the	  N-­‐terminal	  portion	  of	  the	  protein.	  The	  C-­‐terminal	  exons	   in	  FBW7	  encode	  eight	  WD40	  repeats	   that	   form	  a	  barrel-­‐shaped	   beta-­‐propeller	   structure	   that	   is	   responsible	   for	   protein-­‐protein	  interaction	   [64].	  An	  additional	  domain	   in	   the	  N-­‐terminus	  of	   the	  protein,	   termed	  the	  dimerization	  domain	  (DD),	  has	  been	  shown	  to	  mediate	  FBW7	  dimerization	   [65-­‐67].	  While	  all	  FBW7protein	   isoforms	  share	   the	  DD,	  F-­‐box	  and	  WD40	  domains,	   the	  alpha	  and	  gamma	  exons	  lack	  obvious	  domain	  structures,	  whereas	  the	  beta	  isoform	  encode	  a	  putative	   transmembrane	   domain	   (TMD)	   [68-­‐70].	   The	   physiological	   significance	   for	  having	  three	  protein	  isoforms	  with	  exactly	  the	  same	  substrate-­‐binding	  domain	  is	  still	  unclear,	   although	   the	   different	   FBW7	   isoforms	   are	   differentially	   expressed	   among	  different	   tissues.	   Importantly,	   the	   FBW7	   isoforms	   occupy	   different	   subcellular	  compartments	  in	  the	  cell	  [68].	   	  A	  cis-­‐acting	  signal	  in	  the	  5’	  specific	  exons	  directs	  the	  alpha	   and	   beta	   isoforms	   to	   the	   nucleoplasm	   and	   cytoplasm,	   respectively	   [71].	   In	  contrast,	   the	   nuclear	   gamma	   isoform	   also	   localizes	   to	   the	   nucleolus	   [68].	   The	   beta	  isoform	   was	   recently	   reported	   to	   be	   localized	   to	   in	   the	   membrane	   of	   the	  Endoplasmatic	   Reticulum	   (ER)	   [72],	   but	   may	   also	   localize	   to	   mitochondria	   (Steve	  Reed,	  personal	  communication).	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Figure	  4.	  The	  FBW7	  gene	  structure	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2.3.3 Substrates/degrons  The	   interaction	  between	  FBW7	  and	   its	   target	   substrates	   is	   dependent	   on	   a	   specific	  motif	  common	  in	  all	  substrates	  [73,	  74].	  This	  motif	  was	  identified	  through	  structural	  studies	  of	  Cdc4	   in	  S.	  cerevisiae	  and	  a	  human	  phosphopeptide	   from	  cyclin	  E	  [74,	  75]	  and	   was	   named	   the	   Cdc4-­‐Phospho-­‐Degron	   (CPD).	   Importantly,	   data	   from	   several	  substrates	  defined	  a	  CPD	  consensus	  sequence;	  Φ-­‐X-­‐Φ-­‐Φ-­‐Φ-­‐pT/PS-­‐P-­‐P-­‐X-­‐pS/pT/E	  (Φ	  corresponding	  to	  a	  hydrophobic	  residue	  and	  X	  any	  amino	  acid)	  [76],	  which	  is	  found	  in	  all	   target	   proteins.	   Structural	   and	  mutational	   studies	   demonstrated	   that	   the	  major	  contacts	   between	   the	   FBW7	   and	   its	   substrate(s)	   occurs	   through	   hydrogen	   bonds	  between	  a	  phosphorylated	  threonine/serine	  in	  the	  CPD	  and	  several	  arginine	  residues	  located	   in	  a	  binding	  pocket	  on	   the	   inner	   rim	  of	   the	  beta-­‐propeller	   surface	  of	  FBW7	  [69,	   75].	   However,	   the	   affinity	   for	   a	   specific	   substrate	   also	   seem	   to	   depend	   on	   the	  number	  of	  CPDs,	  and	  on	  the	  actual	  amino	  acid	  sequence	  in	  each	  respective	  substrate	  [76].	  To	  date,	  FBW7	  has	  been	  reported	  to	  target	  20	  different	  proteins	  for	  degradation	  (Table	   1)	   and	   as	   such,	   FBW7is	   involved	   in	   the	   regulation	   of	   multiple	   biological	  processes	  (Figure	  5,	  6).	  Importantly,	  the	  common	  denominator	  for	  these	  substrates	  is	  that	   they	   all	   act	   as	   critical	   oncoproteins.	   Some	  of	   these	   substrates	   are	   described	   in	  greater	  detail	  below.	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Table	  1.	  FBW7	  substrates	  in	  mammals	  
	   θ,	  hydrophobic	  amino	  acid;	  X,	  any	  amino	  acid,	  *	  additional	  functions	  	   	   	  
	  
2.3.3.1 Cyclin E1 Cyclin	  E,	  an	  activator	  of	  Cdk2,	  is	  involved	  in	  the	  initiation	  of	  DNA	  replication	  and	  other	  cell	   cycle	   functions	   [77].	   Cyclin	   E/Cdk2	   catalyzes	   the	   phosphorylation	   of	   many	  substrates	  that	  are	  involved	  in	  diverse	  S	  phase	  processes	  such	  as	  histone	  biosynthesis,	  centrosome	  duplication,	  and	  the	  licensing	  of	  origins	  of	  replication	  (ORC),	  among	  others	  [78].	  In	  normal	  cells,	  the	  level	  of	  cyclin	  E	  peaks	  at	  the	  G1/S	  phase	  boundary	  and	  rapidly	  declines	  as	  cells	  progress	  into	  S	  phase.	  However,	  in	  many	  tumors	  cyclin	  E	  protein	  levels	  are	   elevated	   and/or	   dysregulated	   relative	   to	   cell	   cycle	   progression	   and	   these	  
Name	   Degron	   Protein	  category	   Function	  	   θXθθθ(S/T)PXX	  (S/T/E)	   	   	  Cyclin	  E	  	  	   LLTPPQSGK	  IPTPDKEDD	   Regulatory	   Proliferation*	  c-­‐Myc	   LPTPPLSPS	   Transcription	  factor	   Proliferation*	  c-­‐Jun	   GETPPLSPI	   Transcription	  factor	   Proliferation*	  SREBP	  1	  	  	   TLTPPPSDA	   Transcription	  factor	   Metabolism	  SV40	  large	  T	  antigen	  	   PPTPPPEPE	   Oncoprotein	   Transformation	  Notch	  1	  	   FLTPSPESP	   Transcription	  factor	   Differentiation*	  Presenilin	  1	  	   IYTPFTEDT	   Regulatory	   signaling	  Cyclin	  E2	  	   LLTPPQSGK	  IPTPDKEDD	   Regulatory	   Cell	  cycle*	  MCL1	   GSAGASPPST	  ADAIMSPEEE	   regulatory	  	   Apoptosis	  C/EBPalpha	   HPTPPPTP	   Transcription	  factor	   Differentiation	  KLF5	  	   LNTPDLDM	  PPSPPSSE	  	  NLTPPPSY	   transcription	  factor	   Proliferation	  Aurora	  A	   ?	   Kinase	   Proliferation*	  mTOR	   LLTPSIHL	   Kinase	   Proliferation*	  c-­‐Myb	   ?	   Transcription	  factor	   Proliferation	  SRC	   SPMAS	   Transcription	  factor	   Proliferation	  PGC1	   PLTPESPN	  GLTPPTTP	   Transcription	  factor	   Metabolism	  n-­‐Myc	   ?	   transcription	  factor	   Proliferation	  TGIF1	   FNTPPPTP	   regulatory	  	   signaling	  Ebp2	  (pseudosubstrate)	   ?	   Regulatory	   Ribosome	  biogenesis	  PKC	  (atypical	  substrate-­‐no	  degradation)	   ?	   Kinase	   Signaling	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alterations	  have	  a	  strong	  prognostic	   impact	   for	  poor	  outcome	  in	  patients	  with	  breast	  cancer	   [79,	   80].	   Overexpression	   of	   cyclin	   E	   has	   been	   shown	   cause	   a	   premature	  initiation	  of	  DNA	  synthesis	  [77,	  81]	  and	  induce	  chromosome	  instability	  in	  cultured	  cells	  [78].	   	  Furthermore,	  deregulated	  cyclin	  E	  expression	  in	  mice	  leads	  to	  tumor	  formation	  [82].	  Finally,	  cyclin	  E	  can	  transform	  rat	  embryo	  fibroblasts	  together	  with	  oncogenic	  Ras	  [83],	   in	   line	   with	   its	   oncogenic	   function.	   The	   first	   indication	   for	   ubiquitin	   ligase	  mediated	  proteolysis	  of	  cyclin	  E	  was	  provided	  by	  reports	  of	  the	  Cul1	  knockout	  mouse	  [84,	   85].	   Cul1	   deficiency	   in	  mice	   resulted	   in	   embryonic	   lethality	  with	   arresting	   cells	  containing	  elevated	   levels	  of	  cyclin	  E	   [84].	   In	  2001,	   three	  groups	   including	  our	  own,	  independently	  identified	  the	  F-­‐box	  protein	  FBW7	  as	  a	  novel	  SCF	  ligase	  responsible	  for	  cyclin	   E	   ubiquitylation	   and	   degradation	   [69,	   86,	   87].	   FBW7	   was	   found	   to	   bind	  specifically	  to	  cyclin	  E	  that	  is	  phosphorylated	  on	  two	  CPDs,	  one	  surrounding	  Thr62	  and	  one	  at	  Thr380	  [88-­‐91].	  Phosphorylation	  of	  cyclin	  E1	  is	  mediated	  by	  Cdk2	  on	  residues	  Thr380	   and	   Ser384	   through	   autophosphorylation	   and	   also	   by	   glycogen	   synthase	  kinase	   3	   (GSK3)	   [89].	   Interestingly,	   whereas	   FBW7-­‐beta	   does	   not	   appear	   to	   be	  involved	  in	  cyclin	  E	  turnover,	  both	  FBW7-­‐alpha	  and	  gamma	  are	  required	  for	  cyclin	  E	  degradation	  in	  cultured	  cells	  [91,	  92].	  Using	  in	  vitro	  and	  in	  vivo	  ubiquitylation	  assays,	  we	   found	  that	  ubiquitylation	  of	  cyclin	  E	  requires	  sequential	   function	  both	  the	  alpha	  and	  the	  gamma	  isoforms	  [91].	  	  	  
2.3.3.2 Notch 1  The	  Notch1	  gene	  is	  a	  member	  of	  the	  Notch	  family	  of	  transmembrane	  receptors	  [93].	  Notch	  proteins	  have	  an	  extracellular	  domain	  consisting	  of	  multiple	  epidermal	  growth	  factor-­‐like	  (EGF)	  repeats,	  and	  an	  intracellular	  domain.	  Notch	  proteins	  play	  a	  key	  role	  in	   a	   variety	   of	   developmental	   processes	   and	   regulate	   differentiation,	   survival,	   and	  proliferation	   through	   an	   evolutionarily	   conserved	   intercellular	   signaling	   pathway.	  Canonical	   Notch	   signaling	   is	   initiated	   and	   activated	   following	   ligand	   (Jagged)	  interaction	  and	  sequential	  proteolytic	  cleavages	  by	  ADAM	  metalloproteases	  and	   the	  gamma-­‐secretase	   complex	   [93].	   Proteolytic	   release	   of	   the	   intracellular	   domain	   of	  Notch	   (NICD)	   from	   the	   cell	   membrane	   results	   in	   translocation	   of	   the	   NICD	   to	   the	  nucleus	   where	   it	   promotes	   the	   transcriptional	   activation	   of	   DNA-­‐binding	  transcription	  factor	  including	  CSL	  and	  MAM.	  NICD	  forms	  a	  trimeric	  complex	  with	  CSL	  and	   the	   co-­‐activator	   MAM,	   which	   is	   essential	   for	   NICD-­‐dependent	   transcription	   in	  
vitro	   and	   in	   vivo	   [94].	   The	   first	   Notch	   receptor	   gene	   to	   be	   identified	   in	   humans,	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Notch1,	  was	   discovered	   through	   the	   analysis	   of	   DNA	   flanking	   the	   breakpoints	   of	   a	  recurrent	  t(7;9)(q34;q34.3)	  chromosomal	  translocation	  seen	  in	  a	  small	  subset	  (<	  1%)	  of	   human	   pre–T-­‐cell	   acute	   lymphoblastic	   leukemias	   [95].	   Notch1	   is	   frequently	  mutated	  in	  T-­‐ALL	  but	  is	  also	  deregulated	  in	  variety	  of	  other	  human	  tumors,	  including	  breast	   cancer	   and	   various	   subsets	   of	   human	   lymphomas	   [96,	   97].	   The	   first	   link	  between	   Notch	   and	   FBW7	   came	   from	   studies	   demonstrating	   that	   LIN-­‐12	   (the	  NOTCH1	  orthologue	  in	  C.	  elegans)	  is	  regulated	  by	  SEL-­‐10	  (the	  Cdc4	  orthologue	  in	  C.	  elegans)	   [98,	  99].	   In	  2001,	   the	  mouse	  and	  human	  homologs	  of	  FBW7	  was	  shown	  to	  target	   Notch1	   for	   ubiquitylation	   [100].	   Interestingly,	   Notch1	   is	   also	   controlled	   by	  several	  other	  ubiquitin	  ligases	  [99,	  101-­‐103].	  The	  PEST	  domain	  of	  NICD	  is	  known	  to	  regulate	  protein	  stability	  and	  is	  often	  mutated	  in	  primary	  human	  and	  mouse	  T-­‐ALLs	  [104].	   Indeed,	   the	   Notch1	   PEST	   domain	   contains	   putative	   CPD	   motifs	   [105].	   The	  important	  function	  of	  FBW7	  in	  Notch	  regulation	  is	  underscored	  by	  the	  fact	  that	  FBW7	  knockout	  mice	  die	  early	  during	  embryonic	  development	  mainly	  due	  to	  abnormalities	  in	   vascular	   development	  which	   is	   attributed	   to	   failure	   in	   the	   degradation	   of	   Notch	  [103,	  106].	  	  
	  
2.3.3.3  c-Myc The	  MYC	   proto-­‐oncogene	   encodes	   a	   nuclear	   transcription	   factor	   and	   regulates	   up	   to	  15%	   of	   all	   genes	   [107].	   Because	   of	   this,	  MYC	   regulates	   a	   broad	   spectrum	   of	   cellular	  functions,	   including	  cell	  growth,	  proliferation	  and	  apoptosis	  among	  others	  [108-­‐110].	  Loss	  of	  Myc	  results	  in	  embryonic	  lethality	  in	  mice	  and	  depletion	  of	  Myc	  forces	  cells	  to	  exit	  the	  cell	  cycle.	  Conversely,	  Myc	  expression	  stimulates	  progression	  through	  the	  cell	  cycle	   and	   its	   overexpression	   in	   cells	   or	   animals	   induces	   transformation	   [111,	   112].	  Indeed,	   the	  MYC	  gene	   is	  one	  of	   the	  most	   frequently	  overexpressed	  oncogenes	  and	   is	  estimated	   to	   contribute	   to	   as	  many	   as	   70%	  of	   all	   human	   cancers	   [113-­‐116].	   Thus,	   a	  tight	  control	  of	  Myc	  expression	  and	  activity	  is	  essential	  for	  normal	  cellular	  homeostasis.	  Like	  cyclin	  E,	  MYC	  expression	  is	  regulated	  by	  upstream	  kinases	  such	  as	  the	  PI3K-­‐AKT-­‐GSK3b	   pathways,	   which	   is	   responsible	   for	   the	   rapid	   degradation	   of	   Myc	   by	   the	  ubiquitin-­‐proteasome	   pathway.	   Increased	   stability	   of	   Myc	   is	   frequently	   observed	   in	  various	  human	  tumors	  and	  this	  has	  mainly	  been	  attributed	  to	  point	  mutations	  in	  the	  N-­‐terminus	   of	   Myc,	   a	   region,	   which	   also	   encodes	   a	   CPD.	   Indeed,	   subsequent	   studies	  showed	   that	   FBW7	   targets	   Myc	   for	   ubiquitin-­‐mediated	   proteolysis	   in	   a	  phosphorylation	   dependent	   manner	   [117-­‐119].	   The	   exact	   mechanism	   for	   Myc	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ubiquitylation	   is	   not	   known.	   Like	   cyclin	   E,	   Myc	   degradation	   appears	   to	   depend	   on	  additional	   cofactors	   (see	   below)	   and	   both	   the	   nuclear	   isoforms	   of	   FBW7	   [68].	  Interestingly,	  at	  least	  five	  ubiquitin	  ligases	  have	  been	  implicated	  in	  Myc	  ubiquitylation	  and	  turnover,	  including	  three	  F-­‐box	  proteins	  (Cdc4,	  SKP2	  and	  bTRCP)	  [120].	  	  	  
1.3.3.4	  Other	  substrates	  	  As	   mentioned	   above,	   the	   list	   of	   novel	   FBW7specific	   target	   substrates	   is	   rapidly	  expanding,	  as	  is	  the	  number	  of	  biological	  pathways	  regulated	  by	  FBW7.	  Figure	  5	  and	  Table	  1	  summarize	  the	  extensive	  number	  of	  substrates	  we	  know	  today.	  From	  this	  list,	  it	   is	   evident	   that	   FBW7is	   not	   only	   responsible	   for	   the	   tight	   regulation	   of	   the	   cell	  division	   cycle,	   but	   also	   control	   growth,	   signal	   transduction,	   differentiation,	   survival	  and	  metabolism.	  Although	  most	  established	  substrates	  are	  nuclear	  proteins	  degraded	  by	  the	  nuclear	  isoforms	  of	  FBW7,	  alpha	  and	  gamma	  [68],	  it	  is	  intriguing	  that	  there	  are	  yet	   no	   defined	   substrates	   for	   the	   cytoplasmic	   FBW7-­‐beta	   isoform	   [61].	   Whereas	  knockout	   mice	   lacking	   FBW7	   are	   not	   viable,	   a	   recent	   study	   shows	   that	   mice	  specifically	   deleted	   for	   the	   FBW7-­‐beta	   isoform	   do	   not	   exhibit	   any	   apparent	  development	   defects.	   However,	   primary	   cultures	   of	   neurons	   prepared	   from	   the	  mutant	   mice	   are	   more	   sensitive	   to	   oxidative	   stress	   than	   those	   prepared	   from	   the	  wild-­‐type	  mice.	   Conversely,	   overexpression	   of	   FBW7-­‐beta	   renders	   cells	   resistant	   to	  the	  oxidative	  stress.	  These	  results	   thus	  suggest	   that	  FBW7-­‐beta	  might	  contribute	   to	  the	  protection	  of	  cells	  from	  oxidative	  stress	  [72].	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alpha	   isoform.	   Interestingly,	   the	   inflammatory	   response	   gene	   CCAAT/enhancer	  binding	   protein-­‐δ,	   C/EBPδ,	   has	   been	   shown	   to	   directly	   inhibit	   expression	   of	  FBW7during	   hypoxia	   through	   targeting	   the	   promoter	   region	   of	   FBX7-­‐alpha	   [123].	  	  Interestingly,	   we	   recently	   discovered	   that	   the	   gamma	   transcript	   is	   induced	   upon	  serum-­‐withdrawal	   mediated	   myoblast	   differentiation	   of	   C2C12	   cells	   (unpublished	  data).	   Furthermore,	   gene	   expression	   data	   indicate	   that	   FBW7	   expression	   may	   be	  transcriptionally	   induced	   under	   low	   oxygene	   conditions.	   A	   potent	   epigenetic	  mechanism	   for	   the	   regulation	   of	   gene	   expression	   during	   normal	   development	   and	  cellular	   differentiation	   in	   higher	   organisms	   is	   DNA	  methylation	   [124].	  We	   recently	  demonstrated	  that	  the	  beta	  promoter	  is	  hypermethylated	  in	  multiple	  different	  tumor-­‐derived	  cell	   lines	  and	  primary	  breast	   tumors	   (paper	   III)	  and	   it	   is	   thus	  possible	   that	  methylation	  of	  the	  different	  FBW7promoters	  determines	  isoform	  specific	  expression	  in	   different	   normal	   tissues.	   Another	   potential	   mechanism	   for	   regulation	   of	   FBW7	  expression	  is	  microRNAs	  (miRNAs).	  miRNAs	  are	  short	  non-­‐coding	  RNAs	  of	  about	  21-­‐23	   nucleotides	   in	   length	   that	   regulate	   gene	   expression	   at	   the	   post-­‐transcriptional	  level	  [125,	  126].	  Despite	  their	  recent	  discovery,	  miRNAs	  are	  now	  widely	  accepted	  as	  critical	  gene	  expression	  regulatory	  factors	  [125,	  126].	  miRNAs	  are	  expressed	  by	  RNA	  polymerase	  II	  as	  parts	  of	  longer	  primary	  transcripts	  or	  miRNA	  precursors	  termed	  pri-­‐microRNAs	  [127,	  128].	  Maturation	  of	  miRNAs	   involves	  the	  sequential	  processing	  by	  protein	   complexes	   containing	   an	   RNAse	   III	   enzyme	   Drosha	   and	   the	   Dicer-­‐TRBP	  complex	   respectively	   [129],	   followed	   by	   incorporation	   into	   a	   complex	   termed	  RISC	  (RNA-­‐induced	   silencing	   complex)	   [130,	   131].	   The	   degree	   of	   complementarity	  between	  microRNA	   and	  mRNA	  will	   generally	   dictate	   the	   outcome;	   perfect	   or	   near-­‐perfect	   complementarity	   will	   result	   in	   cleavage	   of	   the	   mRNA,	   while	   imperfect	  complementarity	   will	   trigger	   translational	   repression	   [132].	   The	   human	   genome	  contain	   between	   400	   to	   1000	   different	   miRNAs,	   as	   estimated	   by	   computational	  methods	   [133].	   Approximately	   50%	   of	   all	   genes	   are	   predicted	   targets	   of	   miRNAs	  [134].	   Apparently,	   each	  miRNA	   targets	  many	   different	   genes	   and	   each	   3’UTR	   often	  contains	   binding	   sites	   for	   many	   different	   miRNAs	   [135-­‐137].	   Because	   of	   their	  widespread	   role	   in	   regulation	   of	   gene	   expression,	   it	   is	   easy	   to	   understand	   that	  miRNAs	   have	   profound	   effects	   on	   tumor	   development.	   In	   fact,	   many	  miRNAs	   have	  been	  shown	  to	  act	  as	  tumor	  suppressors	  and	  oncogenes	  [22].	  With	  this	   in	  mind,	  we	  set	  out	  to	  identify	  miRNAs	  that	  might	  regulate	  FBW7	  expression.	  Using	  a	  combination	  of	  different	  screening	  procedures,	  we	  found	  that	  the	  3’UTR	  of	  FBW7	  is	  regulated	  by	  at	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least	  5	  different	  miRNAs.	  Interestingly,	  one	  of	  these	  miRNAs,	  miR-­‐27a,	  was	  found	  to	  regulate	  FBW7	  expression	  during	  cell	  cycle	  progression	  (paper	  IV).	  In	  fact,	  this	  is	  the	  first	   demonstration	   that	   FBW7	   expression	   is	   regulated	   during	   specific	   cell	   cycle	  phases	   under	   physiological	   conditions	   (paper	   IV).	   Interestingly,	   miR-­‐223	   was	  recently	  reported	  to	  regulate	  FBW7	  expression	  as	  well	   [138].	   Interestingly,	  miRNAs	  often	   act	   in	   concert	  with	   specific	  RNA	  binding	  proteins.	   It	   is	   becoming	   increasingly	  clear	   that	  miRNA	   function	  often	  depends	  on	  RNA	  binding	  proteins	   [137].	  There	  are	  still	   no	   reports	   on	   the	   role	   of	   RNA-­‐binding	   proteins	   regulating	   FBW7	   expression.	  However,	  our	  results	  indicate	  that	  miR-­‐27a-­‐mediated	  repression	  of	  FBW7	  is	  minimal	  at	   the	  G1/S	  border,	  without	   any	  obvious	   change	   in	  miR-­‐27a	  expression	   levels.	  This	  suggests	  that	  the	  interaction	  between	  miR-­‐27a	  and	  the	  FBW7-­‐3’UTR	  is	  regulated	  by	  additional	   factors,	   as	   has	   been	   demonstrated	   for	   the	   cyclin-­‐dependent	   kinase	  inhibitor	   p27	   mRNA	   and	   the	   miRNAs	   miR-­‐221/miR-­‐222	   which	   is	   dynamically	  regulated	  by	   the	  RNA-­‐binding	  protein	  Pumilio-­‐1	   [139].	  Future	  studies	  will	   reveal	   in	  greater	  detail	  how	  FBW7	  is	  regulated	  by	  miR-­‐27a	  during	  the	  cell	  cycle	  and	  whether	  it’s	  regulated	  by	  specific	  RNA	  binding	  proteins.	  
	  
1.4.1.2	  Activity	  FBW7function	   and	   activity	   is	   also	   regulated	   at	   the	   post-­‐translational	   level.	   As	  described	  above,	  FBW7	  function	  as	  a	  SCF	  ubiquitin	  ligase	  when	  bound	  the	  Skp1-­‐Cul1-­‐Roc1	  complex.	  Thus,	  the	  general	  regulation	  of	  components	  in	  the	  core	  ligase	  is	  also	  of	  importance	   for	   FBW7-­‐specific	   substrate	   ubiquitylation.	   Indeed,	   it	   has	   been	   shown	  that	   SCF	   activity	   requires	   an	   active	  neddylation	   system	   [140].	   	   For	   example,	   recent	  observations	   indicate	   that	   conformational	   changes	   induced	   by	   Cullin-­‐RING	   E3	  ubiquitin-­‐Ligases	  (CRL)	  dimerization	  and	  by	  conjugation	  of	  the	  ubiquitin-­‐like	  protein	  NEDD8	   on	   the	   cullin	   subunit	   stimulates	   substrate	   polyubiquitination	   [141].	  Conversely,	   Deneddylation,	   in	  which	   the	   COP9	   signalosome	   (CSN)	   removes	   NEDD8	  from	   cullins,	   inactivates	   CRLs	   [142].	   Interestingly,	   it	   is	   very	   difficult	   to	   detect	  endogenous	  FBW7	  protein	  expression	  in	  cells	  although	  FBW7	  mRNA	  levels	  are	  easily	  detected.	   The	   reason	   for	   this	   is	   not	   completely	   understood,	   but	   could	   be	   due	   to	  miRNA-­‐mediated	   translational	   repression,	   or	   possibly,	   decreased	   protein	   stability.	  Indeed,	  we,	   (unpublished	  data)	   and	  others	   [143]	  have	   shown	   that	   FBW7	  protein	   is	  unstable	  and	  auto-­‐ubiquitylated	  in	  vivo.	  Notably,	  the	  WD40	  beta-­‐propeller	  structure	  was	   recently	   shown	   to	   function	   as	   an	   ubiquitin-­‐binding	   domain	   and	   ubiquitin	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interaction	   by	   Cdc4	   was	   demonstrated	   to	   promote	   its	   autoubiquitylation	   and	  turnover	  [144].	  	  	  We	  have	  very	  limited	  knowledge	  of	  direct	  post-­‐translational	  modifications	  regulating	  FBW7	  activity.	  However,	  FBW7	  is	  phosphorylated	  through	  ATM/ATR	  pathway	  upon	  induction	   of	  DNA	  damage	   [145].	   Additionally,	   FBW7	  was	   recently	   reported	   to	   be	   a	  novel	   substrate	   for	   PKC	   and	   mutational	   analysis	   revealed	   that	   PKC-­‐mediated	  phosphorylation	   of	   the	   FBW7-­‐alpha	   isoform	   at	   serine	   10	   regulate	   its	   nuclear	  localization	  [146].	  There	  are	  as	  yet	  no	  reports	  for	  post-­‐translational	  modifications	  of	  the	  beta	  and	  gamma	  isoforms.	  	  	  In	  addition	  to	   the	  F-­‐box	  and	  WD40	  domains,	  FBW7	  contains	  a	  dimerization	  domain	  (DD)(Figure	  4)	  located	  immediately	  N-­‐terminal	  to	  the	  F-­‐box	  domain.	  The	  D-­‐domain	  is	  highly	  conserved	  among	  different	  species	  [66,	  147]	  and	  is	  also	  found	  in	  other	  F-­‐box	  proteins.	   For	   example,	   human	   beta-­‐TrCP1	   and	   beta-­‐TrCP2,	   form	   hetero-­‐	   and	  homodimers	  in	  vivo	  [66,	  147]	  and	  the	  two	  FBW7	  homologs	  in	  fission	  yeast,	  Pop1	  and	  Pop2,	   also	   form	   hetero-­‐	   and	   homo-­‐complexes	   [148].	   Human	   FBW7also	   forms	  homodimers	   and	   possibly	   heterodimers	   [67].	   The	   role	   of	   dimerization	   of	   F-­‐box	  proteins	   is	   not	   exactly	   understood,	   but	   has	   been	   proposed	   to	   increase	   the	  ubiquitylation	   efficiency	   of	   substrates	   with	   low-­‐affinity	   phosphodegrons	   [65,	   66],	  possibly	   through	  reducing	   the	  distance	  between	   the	  substrate	  and	   the	  SCF	  catalytic	  site.	   Juxtaposition	   of	   two	   E2	   sites	   in	   proximity	   to	   the	   substrate	   may	   also	   increase	  reaction	   kinetics	   [66].	   However,	   FBW7dimerization	   is	   not	   an	   absolute	   requirement	  for	   cyclin	   E	   degradation	   [65].	   Additional	   studies	   need	   to	   firmly	   establish	   how	  dimerization	   regulates	   substrate	   ubiquitylation.	  Moreover,	   SCFFBW7	   localization	   and	  activity	  is	  also	  regulated	  by	  various	  cofactors.	  We,	  and	  others	  have	  previously	  shown	  that	  SCFFBW7	  mediated	  cyclin	  E	  and	  Myc	  ubiquitylation	  depends	  on	  the	  peptidyl-­‐prolyl	  cis/trans	  isomerase	  Pin1	  [91,	  149].	  Pin1	  is	  a	  multifunctional	  enzyme	  that	  isomerizes	  many	   proteins	   with	   S/TP	   motifs	   [150].	   We	   showed	   that	   ubiquitylation	   of	   cyclin	   E	  requires	   the	  sequential	   function	  of	  FBW7-­‐alpha	  and	  gamma	  isoforms	  [91].	  Whereas	  FBW7-­‐gamma	  polyubiquitylates	  cyclin	  E,	  FBW7-­‐alpha	  forms	  a	  ternary	  complex	  with	  cyclin	  E	  and	  Pin1	  and	   isomerizes	   the	  cyclin	  E	  phosphodegron.	  Pin1	   is	  also	  required	  for	  FBW7	  mediated	  Myc	  degradation,	  in	  conjunction	  with	  the	  protein	  phosphatase	  2A	  (PP2A)	  [118].	  Thus,	  PP2A	  is	  another	  factor	  regulating	  FBW7	  activity	  towards	  specific	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2.3.5 Mechanisms of inactivation  
2.3.5.1 Phenotypes While	   FBW7	   null	   mice	   die	   around	   10.5	   days	   post	   coitus	   due	   to	   a	   combination	   of	  deficiencies	   in	  hematopoietic	  and	  vascular	  development	  attributed	   to	  dysregulation	  of	   Notch1	   [103],	   tumors	   with	   inactivation	   of	   FBW7	   exhibit	   various	   functional	  alterations	   related	   to	   other	   FBW7	   substrates.	   Considering	   the	   fact	   that	   FBW7	  orchestrates	   the	   destruction	   of	   a	   number	   of	   key	   onco-­‐proteins	   it	   is	   maybe	   not	  surprising	  that	  FBW7	  function	  has	  been	  linked	  to	  several	  important	  processes	  such	  as	  proliferation,	   apoptosis	   and	   differentiation.	   Thus,	   FBW7	   inactivation	   causes	   the	  undermined	   regulation	   of	   several	   specific	   cellular	   programmes	   associated	  with	   the	  major	  hallmarks	  of	  cancer	  (Figure	  6).	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Recently	   FBW7-­beta	   deficient	   mice	   have	   been	   generated.	   Interestingly,	   no	   cancer	  development	   was	   detected	   in	   these	  mice	   up	   to	   1	   year.	   Also	   these	   animals	   did	   not	  exhibit	  any	  apparent	  abnormalities	  in	  development,	  however	  longer	  observation	  will	  be	  necessary	  to	  determine	  whether	  Fbxw7b-­‐deficient	  mice	  are	  predisposed	  to	  cancer	  development	  [72].	  	  One	   obvious	   phenotype	   in	   cells	   with	   FBW7	   inactivation	   is	   genetic	   instability	   [162,	  163].	   The	   genetic	   instability	   phenotype	  might	   be	  mediated	   due	   to	   increased	   levels	  and	   dysregulated	   expression	   of	   a	   several	   key	   oncogenic	   FBW7	   target	   substrates,	  including	   c-­‐Myc,	   cyclin	   E1	   and	   STK15/AURKA	   protein	   [164].	   During	   recent	   years	  there	  has	  been	  an	  effort	  to	  show	  which	  of	  these	  substrate(s)	  that	  is	  more	  likely	  to	  be	  responsible	   for	   the	   genomic	   instability	   caused	   by	   FBW7	   ablation,	   with	   ample	   data	  supporting	   the	   relevance	   of	   dysregulated	   cyclin	   E1.	   Overexpression	   of	   cyclin	   E	   can	  also	  recapitulate	  phenotypes	  observed	  in	  cells	  with	  inactivated	  or	  suppressed	  FBW7,	  and	  conversely,	  knockdown	  of	  cyclin	  E	  expression	  in	  cancer	  cell	  lines	  with	  a	  genomic	  instability	   phenotype	   reduces	   percentage	   of	   micronuclei	   formation	   [162].	   Taken	  together,	   cyclin	   E1	   dysregulation	   phenocopies	   several	   phenotypes	   observed	   upon	  ablation	   of	   FBW7[78].	   The	   genomic	   instability	   of	   FBW7-­‐deficient	   cells	   is	   at	   the	  microscopic	   level	   manifested	   as	   nuclear	   atypia	   characterized	   by	   micronuclei,	  lobulated	   or	   elongated	   nuclei,	   aberrant	   chromosomal	   structures	   at	   metaphase,	  abnormal	   number	   of	   centromeres	   and	   multipolar	   spindles	   [162].	   Furthermore,	  FBW7-­‐deficient	   tumor	   cells	   undergo	   extensive	   mitotic	   slippage	   and	  endoreduplication	  when	  exposed	  to	  spindle	  toxins	  such	  as	  vinblastine	  or	  taxol,	  which	  in	  turn	  render	  them	  polyploid	  [165].	  	  	  
2.3.5.2 Mutation   Early	   reports	   analyzing	   the	   FBW7	   gene	   sequence	   identified	   chromosomal	  rearrangements	  and	  mutations	  in	  the	  FBW7	  gene	  in	  human	  tumor-­‐derived	  cell	   lines	  [86,	  87].	   Shortly	   thereafter,	   it	  was	   shown	   that	  primary	  endometrial	   tumors	   contain	  
FBW7	   mutations	   [63].	   Interestingly,	   FBW7	   mutation	   was	   found	   to	   correlate	   with	  cyclin	  E	  dysregulation	  in	  these	  tumors	  [63].	  Mutations	  were	  subsequently	  identified	  in	  colon	  carcinomas	  and	  pancreatic	  cancer	   [63,	  166,	  167].	  Our	  original	  discovery	  of	  
FBW7	   mutations	   in	   primary	   endometrial	   adenocarcinomas	   was	   the	   basis	   for	  continued	   analysis	   of	   FBW7	   mutations	   in	   primary	   tumors.	   Mutational	   analysis	   of	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FBW7	   in	   pediatric	   T-­‐ALL	   showed	   that	   this	   malignancy	   has	   a	   particularly	   high	  frequency	   of	   mutations	   (paper	   I).	   These	   studies	   were	   followed	   up	   with	   a	  comprehensive	   screen	   for	  FBW7	  mutations	   in	  1556	  primary	  human	   tumor	   samples	  from	   twelve	   different	   malignancies	   (paper	   II).	   The	   results	   from	   these	   analysis	  established	  that	  FBW7	  represent	  a	  general	  TSG	  in	  human	  cancers	  [168].	  The	  overall	  mutation	   frequency	   of	   FBW7	   in	   different	   tumors	   is	   6%	   and	   the	   highest	   mutation	  frequencies	  were	  found	  in	  tumors	  of	  the	  bile	  duct	  (cholangiocarcinomas,	  35%),	  blood	  (T-­‐cell	   acute	   lymphocytic	   leukemia,	   31%),	   endometrium	   (9%),	   colon	   (9%),	   and	  stomach	  (6%)	  [168].	  The	  most	  common	  mutations	  in	  FBW7	  are	  missense	  mutations	  of	   three	   arginine	   residues	   (Arg465	   and	   Arg479)	   in	   the	   substrate	   binding	   pocket	   of	  FBW7	  [168,	  169].	  Interestingly,	  these	  mutations	  presumably	  function	  in	  a	  dominant-­‐negative	  manner,	  possibly	  through	  dimerization	  with	  the	  functional	  wild-­‐type	  allele.	  The	   reason	   why	  mutations	   frequently	   occur	   in	   these	   specific	   nucleotides	   of	   FBW7	  (exon	  8	  and	  exon	  9)	  is	  not	  known,	  but	  could	  be	  due	  to	  spontaneous	  deamination	  of	  5’-­‐methylcytosine	   to	   thymine	   in	   DNA.	   Indeed,	   the	   cytosine	   corresponding	   to	   the	  mutation	   hotspot	   at	   nucleotides	   1,435–1,436	   (Arg479)	   is	  methylated	   in	   vivo	   [168].	  Some	  discrepancies	  in	  the	  mutation	  frequencies	  have	  been	  reported.	  For	  example	  in	  T-­‐ALL	  samples,	  FBW7	  has	  been	  shown	  to	  be	  mutated	  between	  10	  to	  30	  %	  [170-­‐172],	  but	   all	   laboratories	   report	   clustering	   of	   mutations	   in	   FBW7	   binding	   pocket.	   One	  plausible	   explanation	   for	   such	   differences	   is	   the	   ethnical	   differences	   between	   the	  patients	  enrolled	  in	  different	  studies.	  Other	  factors	  could	  be	  differences	  in	  sample	  size	  or	  other	  types	  of	  selection	  biases.	  	  Various	   types	  of	   single	  nucleotide	  polymorphisms	   (SNPs)(Synonyme,	  nonsynonyme	  and	  frameshift)	  possibly	  affecting	  FBW7	  function	  have	  been	  reported	  to	  occur	   in	  all	  three	  isoforms	  (ensembl.org).	  	  	  
2.3.5.3  Deletion Deletion	  of	  the	  FBW7	  gene,	  which	  localizes	  chromosome	  4q31	  is	  a	  frequent	  event	  in	  human	  tumors	  and	  occurs	  in	  more	  than	  30%	  of	  all	  neoplasms	  [173].	  Several	  studies	  have	  reported	  deletion	  of	  one	  allele	  at	  4q31	  [173,	  174].	  We	  have	  also	  demonstrated	  small	  deletions	  of	  FBW7	  occurring	  in	  a	  breast	  cancer	  cell	  line	  [87].	  A	  previous	  report	  showed	   that	   FBW7-­‐/+	   mice	   crossed	   with	   p53	   heterozygous	   mice	   have	   a	   greater	  susceptibility	  to	  radiation-­‐induced	  tumors	  [122].	  Interestingly,	  most	  of	  these	  tumors	  retain	  and	  express	   the	  wild-­‐type	  FBW7	  allele,	   indicating	  that	  FBW7	  might	  be	  a	  p53-­‐
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dependent	   haploinsufficient	   tumor	   suppressor	   gene	   [122].	   In	   another	   study	   it	   was	  shown	   that	  FBW7	  exhibited	   intestinal	   tumors	   carry	  heterozygous	  FBW7	  mutations,	  again	   indicative	   of	   FBW7	   being	   a	   haploinsufficient	   tumor	   suppressor	   gene	   [175].	  However,	  in	  these	  studies,	  detailed	  analysis	  of	  FBW7	  isoform	  specific	  expression	  was	  not	  performed.	  	  	  
1.5.1.4	  Methylation:	  Several	   recent	   reports	  have	  shown	   that	  FBW7expression	   is	  downregulated	   in	   some	  tumor	  types,	  including	  gliobastomas	  [176],	  gastric	  [177]	  and	  colorectal	  cancer	  [178].	  However,	   the	   mechanism	   for	   loss	   of	   expression	   was	   not	   clarified	   in	   these	   studies	  [179].	  DNA	  methylation	  is	  generally	  defined	  as	  the	  addition	  of	  a	  methyl	  group	  to	  the	  5	  position	  of	  a	  cytosine	  base,	  but	   it	  can	  occur	  on	  adenine	  base	  as	  well.	  Methylation	   is	  epigenetically	   inherited	   from	  parental	   cells	   to	   the	  daughter	   cells	   upon	   cell	   division.	  [180].	   DNA	   methylation	   is	   an	   important	   mechanism	   for	   the	   regulation	   of	   gene	  expression	   during	   normal	   development	   and	   cellular	   differentiation	   in	   higher	  organisms	  [124,	  180].	  Alterations	  in	  the	  methylation	  pattern,	  particularly	  at	  TSG	  gene	  loci,	   is	  also	  a	  frequent	  event	   in	  cancer	  [124].	   In	  paper	  III,	  we	  report	  that	  FBW7-­beta	  promoter	  is	  hypermethylated	  in	  human	  breast	  cancer	  and	  various	  tumor	  derived	  cell	  lines	   [121,	   181].	   Comparison	   of	   FBW7-­beta	   promoter	   methylation	   and	   FBW7-­‐beta	  expression	   demonstrated	   that	   methylation	   correlates	   with	   loss	   of	   expression,	  suggesting	   that	   promoter	   hypermethylation	   is	   an	   alternative	  mechanism	   for	   FBW7	  gene	   inactivation	   (paper	   III).	   Taken	   together,	   these	   data	   indicate	   that	   methylation	  might	  be	  an	  important	  mechanism	  of	  FBW7-­beta	  gene	  inactivation	  in	  different	  tumor	  types	  [121].	  A	  recent	  report	  showed	  that	  the	  FBW7-­beta	  promoter	  is	  also	  methylated	  in	   thymoma	   [181].	   Whether	   the	   other	   FBW7	   promoters	   are	   methylated	   in	   cancer	  remains	  to	  be	  shown,	  but	  our	  methylation	  analysis	  in	  breast	  cancer	  specimens	  show	  no	  evidence	  for	  hypermethylation	  of	  the	  alpha	  promoter	  (paper	  III).	  	  	  	  	  	  
1.5.1.5	  microRNAs	  miRNAs	  are	  now	  widely	  accepted	  as	  critical	  factors	  involved	  in	  the	  regulation	  of	  gene	  expression	   [125,	   126].	   In	  most	   instances,	   the	  microRNA	  will	   bind	   to	   sites	  within	  3’	  untranslated	   regions	   (3’-­‐UTRs)	   of	   the	   targets.	   Today,	   the	   link	   between	  microRNAs	  and	   tumorigenesis	   is	  well-­‐established	   [125]	   and	  microRNAs	  have	  been	   found	   to	  be	  deleted,	   downregulated	   or	   overexpressed	   in	   many	   different	   tumor	   types	   and	   have	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been	   demonstrated	   to	   function	   as	   both	   tumor	   suppressors	   or	   oncoproteins	   [22].	  
FBW7	   has	   a	   long	   and	   extremely	   well-­‐conserved	   3’-­‐UTR	   with	   multiple	   putative	  microRNA	  binding	   sites.	   Thus,	   FBW7	   is	   likely	   to	   be	   regulated	   by	  miRNAs.	   The	   first	  report	  that	  FBW7	  is	   indeed	  regulated	  by	  miRNAs	  was	  just	  recently	  published	  [138].	  The	  granulocyte	  specific	  miR-­‐223	  was	  identified	  as	  a	  regulator	  of	  FBW7	  using	  a	  screen	  for	  miRNAs	  downregulated	  in	  cyclin	  ET74A,	  T393A	  knock-­‐in	  erythroblasts	  (Xu	  et	  al,	  2010).	  Interestingly,	   miR-­‐223	   is	   responsive	   to	   acute	   alterations	   in	   cyclin	   E	   regulation	   by	  FBW7	  and	  it	  was	  suggested	  that	  miR-­‐223	  is	  part	  of	  a	  feedback	  loop	  connecting	  cyclin	  E	  activity	  to	  the	  regulation	  of	  FBW7	  expression	  [138].	  miR-­‐223	  is	  also	  overexpressed	  in	  several	  solid	  tumors	  [182]	  and	  increased	  expression	  has	  also	  been	  reported	  in	  T-­‐ALL	   [183].	  The	   relationship	  between	  miR-­‐223	  and	  FBW7	   in	   tumors	   is	  however	  not	  known.	  We	  recently	  identified	  miR-­‐223	  and	  five	  additional	  miRNAs,	  miR-­‐27a/b,	  miR-­‐182	   and	   miR-­‐363/92	   as	   potential	   regulators	   of	   FBW7	   expression	   (paper	   IV).	  However,	   our	   data	   suggest	   that	  miR-­‐27a	   is	   the	  most	   general	   regulatory	  miRNA	   for	  FBW7.	   Indeed,	   our	  data	   indicate	   that	  miR-­‐27a	   is	   a	  physiological	   regulator	  of	   FBW7	  expression	  during	   cell	   cycle	  progression	  and	   that	   is	   required	   for	   tight	   regulation	  of	  cyclin	  E	  degradation	   at	   the	  G1/S	  border.	  Thus,	   it	   is	   possible	   that	   overexpression	  of	  miR27	  may	  contribute	   to	  dysregulated	  cyclin	  E	  expression	  and	  tumor	  development.	  Our	  findings	  were	  also	  confirmed	  by	  a	  recent	  study	  demonstrating	  miR27	  as	  critical	  suppressor	   of	   FBW7	   expression	   [184].	   Interestingly,	   in	   this	   study,	   upregulation	   of	  miR-­‐27a	   was	   shown	   to	   contribute	   to	   the	   malignant	   transformation	   of	   human	  bronchial	  epithelial	  cells	  induced	  by	  the	  SV40	  small	  T	  antigen	  [184].	  	  
2.3.5.4 Viruses Many	   major	   TSGs	   have	   been	   shown	   to	   be	   inactivated	   by	   specific	   tumor	   viruses.	  Simian	  virus	  40	   (SV40)	   is	  a	  well-­‐characterized	  member	  of	   the	  polyomavirus	   family.	  The	  SV40	  encodes	  three	  proteins	  based	  on	  alternative	  splicing,	  the	  large	  T	  (LT),	  small	  T	  (ST)	  and	  17	  kT	  antigens	  [185-­‐187].	  	  Interestingly,	  SV40	  Large	  T	  Antigen	  can	  also	  inhibit	  FBW7-­‐driven	  cyclin	  E	  turnover	  in	  vivo	   resulting	   in	   increased	   cyclin	   E	   associated	   kinase	   activity.	   LT	   contains	   a	   CPD,	  which	   is	   recognized	   by	   FBW7	   and	   thus	   alters	   the	   normal	   capacity	   of	   FBW7	   in	  targeting	  other	  substrates	  [187].	  Thus,	  the	  binding	  of	  LT	  to	  FBW7	  occurs	  via	  a	  decoy	  phospho-­‐epitope	  within	  the	  C-­‐terminus	  of	  LT	  that	  closely	  mimics	  the	  consensus	  Cdc4	  phospho-­‐degron	  (CPD)	  found	  within	  FBW7	  substrates	  [187].	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  Human	   adenoviruses	   are	   a	   group	   of	   small	   DNA	   viruses	   that	   are	   capable	   of	  transforming	  rodent	  cells	  in	  culture	  and	  also	  induce	  tumors	  in	  hamsters	  or	  rats.	  Two	  viral	   oncogenes,	   termed	   E1A	   and	   E1B,	   have	   been	   identified	   as	   critical	   factors	   for	  adenoviral	   induced	   transformation	   through	   inactivation	   of	   the	   TSGs	   RB	   and	   p53	  [188].	   A	   recent	   report	   suggests	   that	   E1A	   can	   interfere	   with	   FBW7	   function	   by	  targeting	   the	   SCFFBW7complex	   [189].	   E1A	  was	   found	   to	   directly	   bind	   to	   Roc1/Rbx1	  and	  CUL1	  and	  inhibit	  the	  ubiquitin	  ligase	  activity	  of	  core	  ligase,	  resulting	  in	  impaired	  degradation	  of	   several	  proto-­‐oncogene	  products	   that	   are	  normally	  degraded	  by	   the	  SCFFBW7ubiquitin	  ligase	  [189].	  	  	  
2.3.5.5 Other factors As	  mentioned	  above,	  SCFFBW7	  activity	  is	  regulated	  by	  several	  cofactors	  and	  most	  likely	  various	   post-­‐translation	   modifications	   that	   could	   be	   of	   major	   importance	   for	  inactivation	  of	  FBW7	  in	  cancer.	  There	  are	  contradictory	  results	  regarding	  the	  role	  of	  Pin1	   in	   tumorigenesis	   [152,	   154,	   155]	   but	   it	   could	   potentially	   interfer	   with	   FBW7	  function	   [91].	   The	   deubiquitylating	   enzyme	   USP28	   has	   been	   shown	   to	   be	  overexpressed	   in	   colon	   and	   breast	   carcinoma	   [156]	   and	   could	   possibly	   prevent	  FBW7-­‐mediated	   degradation	   cyclin	   E	   and	   c-­‐Myc	   [157].	   Other	   cofactors,	   including	  NPM	   and	   Ebp2	   could	   also	   in	   principle	   also	   interfere	   with	   FBW7	   substrate	  degradation.	   Indeed,	   NPM	   is	   frequently	   mutated	   in	   AML	   and	   NPM	  mutations	   have	  been	  demonstrated	  to	  mislocalize	  FBW7	  protein	  [190].	  Upstream	  signaling	  cascades	  stimulating	   FBW7	   substrate	   degradation,	   including	   the	   GSK3b	   [191]	   and	   the	   Ras	  [192]	  pathway,	  are	  frequently	  dysregulated	  in	  human	  tumors	  and	  may	  therefore	  be	  of	  major	  importance	  preventing	  FBW7	  from	  degrading	  specific	  oncoproteins.	  	  	  	  	  	  	  	  	  
2.4 TARGETING THE UPS IN CANCER 	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During	  recent	  years	  there	  have	  been	  major	  efforts	  to	  develop	  drugs	  targeting	  the	  UPS	  system	   in	   cancer	   cells	   [193].	   The	   fact	   that	   the	   UPS	   regulates	   important	   tumor	  suppressors	  first	  raised	  the	  possibility	  that	  inhibition	  of	  the	  26S	  proteasome	  might	  be	  beneficial	  in	  the	  treatment	  of	  cancer	  patients.	  However,	  targeting	  the	  26S	  proteasome	  will	   also	   stabilize	   critical	   oncoproteins	   and	   it	   is	   not	   possible	   to	   predict	  whether	   the	  inhibition	   of	   the	   26S	   proteasome	   will	   necessarily	   be	   beneficial.	   Nevertheless,	  Bortezomib	   (Velcade),	   a	   reversible	   inhibitor	   of	   the	   chymotrypsin-­‐like	   activity	   of	   the	  26S	  proteasome,	  was	  approved	  by	  the	  US	  Food	  and	  Drug	  Administration	  (FDA)	  for	  the	  treatment	  of	   relapsed	  or	   refractory	  multiple	  myeloma	   in	  2004.	  Today,	  Bortezomib	   is	  used	   for	   the	   treatment	   of	   hematologic	  malignancies	   as	  well	   as	   solid	   tumors	   such	   as	  breast	  cancer	  and	  several	  clinical	  trials,	  utlizing	  Bortezomib	  in	  combination	  with	  other	  drugs	  are	  ongoing	  [190,	  194-­‐198].	  However,	  more	  specific	  drugs	  are	  warranted.	  The	  E3	  ligases	   are	   particularly	   attractive	   drug	   targets	   since	   they	   are	   responsible	   for	   the	  recognition	   and	  ubiquitylation	   of	   specific	   substrates.	   In	   addition,	   it	   is	   now	   clear	   that	  one	  single	  E3	  ligase	  often	  targets	  multiple	  proteins	  for	  degradation.	  For	  example,	  the	  F-­‐box	   protein	   oncoprotein	   Skp2,	   targets	   several	   important	   tumor	   suppressor	   proteins,	  including	   the	   CDK	   inhibitor	   p27	   [199],	   which	   is	   frequently	   downregulated	   in	   many	  different	  tumors	  [200].	  As	  outlined	  in	  this	  thesis,	  FBW7	  also	  targets	  multiple	  proteins	  for	  degradation,	  all	  being	  critical	  oncoproteins.	  Furthermore,	  we	  recently	  showed	  that	  the	  small-­‐molecule	  inhibitor,	  RITA,	  reactivates	  p53-­‐induced	  FBW7	  expression	  resulting	  in	  proteasomal	  degradation	  of	  several	  FBW7	  target	  substrates	  [201].	  Interestingly,	  our	  results	   indicate	   that	   FBW7	   inactivation	   is	   associated	  with	   a	   favorable	   prognosis	   and	  increased	  survival	  (paper	  I,	  III,	  IV).	  The	  reason	  for	  this	  is	  presently	  unclear.	  However,	  exciting	  results	  demonstrating	  synthetic	  lethal	  interaction	  for	  certain	  genes,	   including	  ATM	  and	  p53	   [202],	   and	  PARP	  and	  BRCA1	   [203],	  may	  hint	   that	  FBW7	  could	  also	  be	  synthetic	  lethal	  with	  specific	  genes.	  A	  recent	  study	  identified	  a	  compound	  that	  act	  as	  an	  inhibitor	  of	  SCFCdc4	  in	  yeast	  [204],	  demonstrating	  that	  this	  type	  of	  E3	  ligase	  can	  in	  principle	  be	  inactivated	  by	  small-­‐molecules.	  The	  future	  will	  clarify	  whether	  targeting	  FBW7	  or	  its	  cofactors	  with	  drugs	  can	  be	  used	  in	  the	  treatment	  of	  patients	  with	  cancer.	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3 AIMS OF THIS THESIS The	  overall	  aim	  of	  this	  thesis	  was	  to	  explore	  the	  mechanisms	  by	  which	  FBW7is	  inactivated	  in	  human	  cancers.	  	  
Specific	  aims:	  
	  -­‐	  To	  investigate	  if	  FBW7is	  mutated	  in	  pediatric	  B-­‐	  and	  T-­‐ALLs	  (paper	  I)	  	  -­‐	  To	  elucidate	  if	  FBW7is	  a	  general	  tumor	  suppressor	  gene	  (Paper	  II)	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4 RESULTS AND DISCUSSIONS 	  
4.1 PAPER I The	  Tumor	  Suppressor	  Gene	  hCDC4	  Is	  Frequently	  Mutated	  in	  Human	  T-­‐Cell	  Acute	  Lymphoblastic	  Leukemia	  with	  Functional	  Consequences	  for	  Notch	  Signaling.	  
 At	  the	  beginning	  of	  this	  project,	  very	  little	  was	  known	  about	  whether	  FBW7	  is	  mutationally	  inactivated	  in	  specific	  tumors.	  The	  findings	  that	  Notch1	  is	  a	  novel	  FBW7	  target	  substrate	  that	  is	  frequently	  targeted	  by	  gain	  of	  function	  mutations	  in	  T-­‐ALL	  prompted	  us	  to	  investigate	  the	  possibility	  that	  FBW7	  inactivation	  contributes	  to	  the	  development	  of	  pediatric	  leukemia.	  	  We	  used	  SSCP	  (Single	  Strand	  Conformation	  Polymorphism	  assay)	  and	  sequence	  analysis	  to	  screen	  the	  entire	  coding	  region	  of	  FBW7	  and	  Notch1	  in	  26	  pediatric	  leukemic	  T-­‐	  and	  20	  B-­‐lineage	  ALL	  samples.	  	  	  	  Interestingly,	  FBW7	  mutations	  were	  found	  in	  8	  of	  the	  26	  T-­‐ALL	  specimens	  (31%)	  while	  no	  mutations	  were	  observed	  in	  leukemic	  cells	  from	  B-­‐ALL	  patients.	  All	  mutations	  were	  missense	  mutations	  and	  the	  majority	  (88%)	  led	  to	  aminoacid	  changes	  of	  Arginine	  465	  and	  Arginine	  479,	  which	  are	  located	  within	  the	  substrate	  recognition	  site	  of	  FBW7.	  FBW7	  mutations	  were	  absent	  in	  cells	  from	  matching	  nonmalignant	  leukocytes	  obtained	  from	  the	  same	  patients,	  indicating	  that	  these	  mutations	  were	  of	  somatic	  origin.	  Additionally,	  similar	  mutations	  were	  also	  found	  in	  several	  cell	  lines	  derived	  from	  various	  hematological	  malignancies,	  particularly	  of	  T-­‐cell	  origin.	  No	  hCDC4	  mutations	  were	  identified	  in	  any	  other	  leukemia	  or	  lymphoma	  cell	  lines	  analyzed,	  with	  the	  exception	  of	  the	  multiple	  myeloma	  cell	  line	  U266-­‐1984,	  which	  harbored	  an	  Arginine	  505	  missense	  mutation.	  Notably,	  one	  leukemic	  sample	  was	  found	  to	  harbor	  a	  Notch1	  missense	  mutation	  resulting	  in	  a	  threonine	  to	  methionine	  substitution	  at	  position	  2,484	  in	  the	  PEST	  domain	  of	  Notch1.	  The	  amino	  acids	  surrounding	  threonine	  2484	  in	  Notch1	  resembles	  a	  consensus	  CPD	  motif,	  suggesting	  that	  this	  mutation	  might	  prevent	  its	  recognition	  by	  FBW7.	  However,	  several	  truncating	  PEST	  domain	  mutations	  occur	  downstream	  of	  this	  motif,	  which	  suggests	  that	  multiple	  CPD	  motifs	  may	  be	  present	  in	  Notch1	  ICD	  and	  regulate	  its	  degradation	  [74].	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In	  line	  with	  Notch1	  being	  a	  FBW7	  substrate,	  Notch1	  protein	  analysis	  in	  T-­‐ALL	  cell	  lines	  showed	  that	  cell	  lines	  with	  hCDC4	  mutations	  had	  elevated	  levels	  and	  increased	  stability	  of	  Notch1	  ICD,	  as	  compared	  with	  T-­‐ALL	  cell	  lines	  where	  hCDC4	  was	  not	  mutated.	  Furthermore,	  we	  found	  that	  wild-­‐type	  (wt),	  but	  not	  mutant	  FBW7-­
alpha/gamma	  isoforms,	  could	  restore	  ubiquitylation	  of	  Notch1	  in	  vivo,	  and	  that	  expression	  of	  wt-­‐FBW7	  (but	  not	  mutant	  FBW7)	  decreased	  Notch1	  signaling.	  	  	  Importantly,	  our	  data	  indicated	  that	  mutations	  in	  Notch1	  and/or	  FBW7	  associates	  with	  a	  favorable	  long-­‐term	  survival	  in	  children	  with	  T-­‐ALL.	  This	  was	  the	  first	  report	  showing	  that	  FBW7is	  mutated	  in	  pediatric	  T-­‐ALL	  with	  functional	  consequences	  for	  Notch	  signaling.	  Previous	  studies	  from	  our	  group	  and	  others	  reported	  FBW7	  mutations	  in	  endometrial	  adenomcarcinomas	  [63]	  and	  colon	  [167].	  However,	  the	  mutation	  frequency	  in	  those	  solid	  tumors	  were	  lower	  (16%	  and	  6%).	  	  	  In	  summary,	  previous	  work	  had	  shown	  that	  Notch1	  signaling	  is	  commonly	  upregulated	  in	  T-­‐ALL.	  In	  this	  paper,	  we	  show	  that	  the	  negative	  regulator	  of	  Notch1,	  FBW7,	  is	  frequently	  mutated	  in	  T-­‐ALL.	  This	  data	  also	  extends	  previous	  findings,	  and	  suggests	  that	  mutation	  in	  hCDC4	  and/or	  NOTCH1	  is	  associated	  with	  improved	  overall	  survival	  of	  children	  with	  T-­‐ALL.	  The	  finding	  that	  two	  genes	  in	  the	  same	  pathway,	  NOTCH1	  and	  FBW7,	  are	  both	  frequently	  mutated	  in	  children	  with	  T-­‐ALL	  is	  remarkable	  and	  emphasizes	  the	  importance	  of	  this	  pathway	  in	  T-­‐ALL	  development	  and	  possibly	  therapeutic	  intervention	  and	  refined	  risk	  stratification.	  	  	  	  	  
4.2 PAPER II FBXW7/hCDC4	  Is	  a	  General	  Tumor	  Suppressor	  in	  Human	  Cancer.	  	  Inspired	  by	  the	  frequent	  mutations	  of	  FBW7	  found	  in	  T-­‐ALL,	  we	  wondered	  whether	  FBW7	  is	  inactivated	  in	  other	  tumors	  as	  well,	  and	  if	  it	  could	  represent	  	  a	  general	  tumor	  suppressor	  gene	  in	  human	  malignancy.	  	  	  A	  total	  of	  534	  primary	  tumor	  specimens	  from	  12	  different	  tumor	  types	  were	  included	  in	  this	  study	  and	  analyzed	  by	  SSCP	  (Single	  Strand	  Conformation	  Polymorphism	  assay)	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and	  sequence	  analysis	  for	  mutations	  in	  all	  13	  exons,	  including	  sequences	  unique	  to	  the	  three	  isoforms,	  alpha,	  beta	  and	  gamma.	  We	  next	  compiled	  these	  results	  with	  pre-­‐existing	  FBW7	  mutation	  data	  (a	  total	  of	  1556	  samples).	  Table	  2	  summarizes	  of	  the	  mutational	  analysis.	  	  	  
Table	  2.	  Summary	  of	  FBW7	  mutational	  analysis	  	  
Mutation	  type	   Percentage	  (%)	   Additional	  information	  Single	  amino	  acid	  change	   96	   (missense	  	  	  74%,	  nonsense	  	  	  26%)	  Deletion	  and	  insertion	   4	   	  Isoform	  specific	  mutations	   6	   	  
Average	  mutation	  frequency	   6	   87	  mutations	  out	  of	  1556	  	  
Tumor	  types	   	   	  Breast	   0.8	   	  Bladder	   0	   	  Cholangiocarcinoma	   35	   	  Colon	   9.5	   	  Endometrium	   9	   	  esophagus	   0	   	  Leukemia	  	   	  31	   T-­‐ALL	  (31%),	  B-­‐ALL	  (0),	  B-­‐CLL	  (0),	  HCL	  (0),	  AML	  (0)	  Liver	   0	   	  Lung	   3	   NSCLC	  Melanoma	   0	   	  Bone	   0	   	  Ovarian	   0	   	  Prostate	   1	   A	  proline	  insertion	  in	  Alpha	  isoform	  Pancreas	   9	   Only	  one	  study	  (1	  mutation	  in	  11	  patients)	  Stomach	   15	   	  	  Abbreviations:	  B-­‐CLL,	  B-­‐cell	  chronic	  lymphocytic	  leukemia;	  B-­‐ALL,	  B-­‐cell	  acute	  lymphocytic	  leukemia;	  T-­‐ALL,	  T-­‐cell	  acute	  lymphocytic	  leukemia;	  HCL,	  hairy	  cell	  leukemia;	  NSCLC,	  non–small	  cell	  lung	  carcinoma.	  	  Analysis	  of	  this	  large	  set	  of	  tumors	  confimed	  and	  extended	  previous	  analysis.	  The	  majority	  of	  the	  mutations	  cluster	  in	  the	  critical	  arginines	  previously	  shown	  to	  be	  responsible	  for	  the	  interaction	  between	  FBW7	  and	  the	  phosphodegron	  of	  specific	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substrates.	  Thus,	  mutations	  clustered	  at	  hotspot	  codons,	  encoding	  several	  arginine	  residues	  in	  the	  FBW7	  WD40	  repeats.	  	  	  Investigation	  of	  the	  mutational	  hotspots	  showed	  that	  all	  are	  centered	  on	  CG	  dinucleotides,	  which	  are	  potential	  sites	  of	  DNA	  methylation	  and	  a	  source	  for	  mutations	  due	  to	  deamination	  of	  5’methylcytosine	  to	  thymidine	  in	  DNA.	  	  	  	  Indeed,	  we	  could	  show	  that	  the	  cytosine	  at	  the	  hotspot	  codon	  479	  was	  methylated	  	  in	  all	  tumors	  analyzed.	  Thus,	  these	  mutations	  seem	  to	  correspond	  to	  methylated	  CG	  sites,	  which	  could	  explain	  the	  high	  frequency	  of	  such	  missense	  mutations.	  	  To	  examine	  the	  consequence	  on	  substrate	  binding	  of	  the	  hotspot	  mutations,	  we	  analyzed	  their	  ability	  to	  bind	  one	  of	  the	  FBW7	  key	  substrates,	  cyclin	  E.	  None	  of	  the	  mutants	  could	  bind	  cyclin	  E	  (in	  contrast	  to	  wt-­‐FBW7)	  and	  this	  was	  not	  due	  to	  mislocalization	  of	  the	  FBW7	  mutants.	  	  	  Regarding	  the	  fact	  that	  majority	  of	  the	  mutations	  were	  heterozygous	  raised	  the	  possibility	  that	  these	  mutations	  might	  interfere	  with	  the	  protein	  expressed	  from	  the	  normal	  wild-­‐type	  allele	  of	  FBW7.	  Indeed,	  when	  co-­‐expressed,	  mutant-­‐FBW7	  resulted	  in	  a	  marked	  accumulation	  of	  cyclin	  E1	  despite	  expression	  of	  wt-­‐FBW7.	  These	  results	  are	  well	  in	  agreement	  with	  findings	  that	  FBW7	  forms	  dimers	  in	  vivo	  and	  it	  is	  therefore	  possible	  that	  mutations	  in	  only	  one	  allele	  of	  FBW7	  is	  enough	  to	  compromise	  substrate	  degradation	  through	  a	  dominant-­‐negative	  function.	  	  	  Interestingly,	  our	  analysis	  also	  demonstrates	  that	  mutations	  occur	  in	  the	  unique	  isoform	  specific	  5’-­‐exons.	  The	  functional	  consequences	  of	  mutations	  in	  specific	  isoforms	  are	  not	  fully	  understood,	  but	  could	  for	  example	  to	  mislocalization	  of	  a	  specific	  isoform.	  Indeed,	  we	  could	  show	  that	  a	  proline	  insertion	  in	  a	  prostate	  cancer	  specimen	  that	  resided	  at	  the	  amino	  acid	  16	  of	  the	  FBW7-­‐alpha	  isoform	  mislocalized	  FBW7-­‐alpha	  to	  the	  cytoplasm	  and	  thus	  preventing	  it	  from	  interacting	  with	  cyclin	  E1.	  Additionally,	  one	  FBW7-­‐alpha	  specific	  mutation	  has	  been	  shown	  to	  disrupt	  the	  interaction	  between	  FBW7	  and	  its	  cofactor	  Pin1	  [91].	  Together,	  these	  data	  suggest	  that	  FBW7	  isoforms	  are	  non-­‐redundant.	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In	  summary,	  this	  paper	  is	  the	  first	  comprehensive	  screen	  for	  mutations	  in	  FBW7	  in	  diverse	  human	  tumor	  types.	  The	  results	  demonstrate	  an	  overall	  average	  mutation	  frequency	  of	  6%	  and	  potential	  dominant	  negative	  hotspot	  mutations	  clustering	  in	  exon8	  and	  exon9	  of	  FBW7.	  	  	  	  
4.3 PAPER III Inactivation	  of	  FBXW7/hCDC4-­‐b	  expression	  by	  promoter	  hypermethylation	  is	  associated	  with	  favorable	  prognosis	  in	  primary	  breast	  cancer.	  	  During	  the	  work	  with	  paper	  II,	  it	  became	  obvious	  that	  many	  tumors	  lack	  mutations	  in	  
FBW7,	  although	  several	  of	  these	  tumors	  are	  known	  to	  have	  increased	  levels	  of	  specific	  FBW7	  target	  substrates.	  For	  example,	  elevated	  cyclin	  E	  levels	  are	  frequently	  observed	  in	  breast	  tumors,	  but	  FBW7	  is	  not	  found	  to	  be	  mutated	  in	  this	  malignancy.	  In	  addition,	  our	  preliminary	  analysis	  of	  FBW7	  expression	  in	  both	  primary	  tumors	  and	  derived	  cell	  lines	  indicated	  that	  the	  expression	  of	  FBW7	  varied	  significantly	  between	  and	  within	  different	  tumor	  types.	  	  	  	  	  	  In	  the	  present	  study,	  we	  therefore	  examined	  the	  possibility	  that	  FBW7	  expression	  is	  downregulated	  through	  promoter	  specific	  hypermethylation,	  as	  an	  alternative	  epigenetic	  mechanism	  for	  inactivation	  of	  FBW7	  in	  cancer.	  	  The	  FBW7-­‐	  beta	  isoform	  was	  chosen	  	  for	  further	  analysis;	  since	  it	  showed	  the	  most	  variable	  expression	  pattern	  among	  a	  panel	  of	  different	  tumor-­‐derived	  and	  immortalized	  cell	  lines.	  	  Interestingly,	  using	  bisulphate	  sequenceing	  and	  methylation-­‐sensitive	  restriction	  digestion	  analysis,	  we	  found	  that	  the	  FBW7-­beta	  promotor	  is	  heavily	  methylated	  in	  multiple	  tumor	  cell	  lines.	  Expression	  analysis	  showed	  that	  hypermethylation	  of	  the	  beta-­‐	  promoter	  associates	  with	  a	  decreased	  expression	  of	  the	  FBW7-­‐beta	  mRNA.	  In	  order	  to	  establish	  a	  direct	  link	  between	  methylation	  and	  expression	  we	  treated	  cells	  with	  a	  methylated	  beta-­‐	  promoter	  with	  the	  demethylating	  agent,	  5-­‐AZA	  cytidine	  (AZA).	  Bisulphite	  sequencing	  and	  expression	  analysis	  revealed	  that	  expression	  of	  FBW7-­‐beta	  was	  restored	  and	  its	  promotor	  was	  demethylated	  upon	  5-­‐AZA	  treatment.	  Additional	  investigations,	  including	  luciferase	  reporter	  assays	  with	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an	  in	  vitro	  methylated	  promoter,	  also	  support	  the	  conclusion	  that	  FBW7-­beta	  expression	  is	  regulated	  by	  promotor	  specific	  methylation.	  	  	  	  	  We	  next	  asked	  whether	  FBW7-­beta	  methylation	  also	  occurs	  in	  primary	  tumors.	  A	  total	  of	  161	  breast	  cancer	  specimens,	  from	  two	  independent	  cohorts	  (Austria	  and	  Sweden),	  were	  subject	  to	  methylation	  and	  expression	  analysis.	  The	  methylation	  status	  in	  each	  tumor	  sample	  was	  defined	  by	  restriction	  digestion	  test	  using	  McrBc	  enzyme.	  This	  method	  uses	  methylation-­‐sensitive	  restriction	  McrBc	  enzyme,	  to	  cleave	  DNA	  at	  specific	  methylated-­‐cytosine	  residues	  followed	  by	  amplification	  of	  the	  resultant	  products.	  The	  PCR	  amplification	  bands	  were	  then	  subject	  to	  quantification	  using	  Image	  J	  software.	  	  	  FBW7	  isoform	  specific	  mRNA	  expression	  levels	  were	  analyzed	  by	  real	  time	  PCR	  (RT-­‐PCR).	  Importantly	  promoter	  methylation	  was	  absent	  in	  normal	  breast	  tissue	  (and	  in	  other	  noncancerous	  tissue	  DNA	  extracted	  from	  paraffin-­‐embedded	  breast	  cancer	  specimens).	  	  	  A	  total	  of	  71	  out	  of	  139	  (51%)	  patient	  samples	  showed	  significant	  methylation	  of	  the	  beta	  promoter	  as	  defined	  by	  McrBc	  digestion,	  compared	  to	  its	  undigested	  control.	  Thus,	  as	  in	  tumor	  cell	  lines,	  there	  was	  a	  significant	  inverse	  correlation	  between	  promoter	  methylation	  and	  FBXW7/hCDC4beta	  expression	  in	  primary	  breast	  cancer	  specimens.	  	  	  Interestingly,	  comparison	  of	  the	  FBW7-­beta	  promoter	  methylation	  status	  of	  the	  individual	  samples	  with	  various	  clinicopathological	  factors,	  demonstrated	  that	  methylation	  associates	  with	  high-­‐grade	  tumors	  (p=	  0.017)	  and	  possibly	  estrogen	  receptor-­‐negative	  tumors	  (p=0.08),	  thus	  tumors	  usually	  associated	  with	  an	  adverse	  prognosis	  in	  breast	  cancer.	  Remarkably,	  methylation	  of	  the	  FBW7beta	  promoter	  was	  anyhow	  found	  to	  be	  associated	  with	  a	  decreased	  risk	  of	  death	  ((cohort	  1	  hazard	  ratio	  0.53	  (0.23	  to	  1.23)	  and	  cohort	  2	  (HR)	  0.50	  (95%	  CI	  0.23	  to	  1.08))	  in	  both	  cohorts	  despite	  the	  correlation	  between	  methylation	  and	  high-­‐grade	  tumors.	  When	  methylation	  was	  compared	  to	  overall	  survival	  in	  defined	  subgroups	  of	  the	  breast	  cancer,	  including	  patients	  with	  p53	  mutation	  or	  lymph	  node	  negative	  tumors,	  patients	  with	  a	  methylated	  beta	  promotor	  had	  an	  improved	  overall	  survival.	  	  In	  summary,	  this	  study	  is	  the	  first	  report	  of	  FBW7	  promoter	  hypermethylation	  and	  loss	  of	  expression	  in	  primary	  tumors.	  Our	  data	  support	  promoter	  methylation	  as	  an	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alternative	  mechanism	  for	  FBW7	  inactivation	  in	  cancer.	  The	  frequency	  of	  methylation	  is	  high	  (>50%)	  and	  links	  loss	  of	  FBW7-­‐beta	  expression	  to	  high-­‐grade	  tumors.	  However,	  patients	  with	  a	  methylated	  beta	  promotor	  still	  appear	  to	  have	  a	  decreased	  risk	  of	  death.	  The	  reason	  why	  methylation	  is	  linked	  to	  improved	  survival	  is	  presently	  unclear,	  but	  could	  possibly	  relate	  to	  increased	  sensitivity	  of	  methylated	  tumors	  to	  certain	  therapeutic	  drugs.	  This	  possibility,	  and	  its	  potential	  as	  a	  novel	  biomarker	  are	  areas	  that	  need	  further	  investigation.	  	  	  
4.4 PAPER IV miRNA-­‐27a	  controls	  FBW7/hCDC4-­‐dependent	  Cyclin	  E	  degradation	  and	  cell	  cycle	  progression.	  	  In	  paper	  III,	  we	  showed	  that	  FBW7	  expression	  is	  regulated	  by	  methylation	  of	  specific	  CpG	  dinucleotides	   in	   the	  5’	  UTR	  of	  FBW7.	  Another	  mechanism	  for	  regulation	  of	  gene	  expression	  is	  through	  miRNA	  binding	  to	  specific	  seed	  sequences	  in	  the	  3’UTR	  of	  genes	  [205].	  	  Interestingly,	  the	  FBW7	  3’UTR	  is	  long	  and	  extremely	  conserved	  and	  contains	  a	  large	  number	  of	  putative	  miRNA	  binding	  sites.	  	  The	  aim	  of	  this	  study	  was	  therefore	  to	  investigate	  if	  FBW7expression	  is	  regulated	  by	  miRNAs.	  	  	  An	  initial	  observation	  that	  FBW7	  protein	  expression	  is	  elevated	  in	  cells	  with	  a	  targeted	  deletion	  of	  the	  miRNA-­‐processing	  enzyme,	  Dicer,	  suggested	  that	  FBW7	  3’UTR	  is	  indeed	  controlled	  by	  miRNAs	  	  .	  	  	  In	   order	   to	   identify	   relevant	   candidate	   microRNAs	   that	   potentially	   repress	  FBW7expression,	  we	  employed	  a	  combination	  of	  computational	  predictions,	  luciferase	  reporter	   assays,	  miRNA	   library	   screens	   and	   expression	   profiling	   analysis.	   Luciferase	  reporter	  assays	  was	  initially	  utilized	  to	  identify	  cell	  lines	  where	  FBW7	  is	  repressed	  by	  endogenous	   miRNA	   expression.	   miRNA	   expression	   profiling	   in	   combination	   with	  computer-­‐based	  prediction	  of	  candidate	  miRNAs	  and	  a	  miRNA	  library	  screen	  identified	  miR-­‐27a	  as	  a	  strong	  candidate	  for	  the	  repressive	  effect	  in	  the	  model	  cell	  lines	  utilized.	  	  	  Further	   validation	   analysis	   confirmed	   that	   miR-­‐27a	   is	   a	   negative	   regulator	   of	  FBW7expression.	  Mutation	  of	  two	  putative	  miR-­‐27a	  binding	  sites	  located	  in	  the	  3’UTR	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region	  of	  FBW7completely	  abolished	  the	  suppressive	  effect	  of	  miR-­‐27a	  and	  inhibition	  of	   miR-­‐27a	   by	   antagomirs	   increased	   FBW7	   expression.	   In	   addition,	   miR-­‐27a	  overexpression	   reduced	   endogenous	   FBW7	   protein	   levels	   in	   a	   dose-­‐dependent	  manner.Together,	  these	  results	  confirm	  a	  direct	  function	  for	  miR-­‐27a	  in	  the	  negative	  regulation	  of	  FBW7.	  	  To	   evaluate	   the	   functional	   effect	   of	   miR-­‐27a	   on	   FBW7,	   we	   performed	   several	  experiments	  to	  test	  if	  miR-­‐27a	  specifically	  regulates	  the	  stability	  and	  ubiquitylation	  of	  FBW7target	  substrates.	  miR-­‐27a	  overexpression	  resulted	  increased	  steady-­‐state	  levels	  of	   cyclin	   E	   and	   myc	   which	   was	   due	   to	   an	   increased	   stability	   and	   decreased	  ubiquitylation	  of	  these	  proteins.	  	  	  To	  date,	  we	  have	  very	  limited	  knowledge	  on	  if	  and	  how	  FBW7	  is	  regulated	  during	  the	  cell	   cycle.	   To	   directly	   test	   if	   miR-­‐27a	   regulates	   FBW7	   during	   the	   cell	   cycle,	   we	  analyzed	  FBW7-­3’UTR	  reporter	  activity	  (by	  comparing	  the	  wild-­‐type	  3’UTR	  with	  the	  miR-­‐27a-­‐mutated	   3’UTR)	   in	   U2OS	   cells	   progressing	   from	  mitosis	   towards	   S-­‐phase.	  	  Importantly,	  miR-­‐27a	  was	  found	  to	  potently	  repress	  FBW7	  at	  the	  G2/M	  and	  early	  G1	  phases,	  but	  not	  at	  the	  G1/S	  transition.	  First	  of	  all,	  these	  results	  provide	  evidence	  that	  miR-­‐27a	   regulates	   FBW7	   in	   a	   physiological	   setting,	   during	   cell	   cycle	   progression.	  Second,	   the	   lack	   of	   repression	   at	   the	   G1	   to	   S-­‐border,	   indicate	   that	   miR-­‐27a	   may	  release	   FBW7	   from	   repression	   at	   this	   critical	   cell	   cycle	   stage,	   just	   prior	   to	   FBW7-­‐mediated	   cyclin	   E	   degradation	   at	   early	   S-­‐phase.	   Third,	   overexpression	   of	   miR-­‐27a	  significantly	   elevated	   cyclin	   E	   levels	   in	   later	   cell	   cycle	   stages	   and	   increased	   the	  number	  of	  cells	  S-­‐phase.	  In	  line	  with	  these	  results,	  miR27	  overxoression	  induced	  DNA	  double-­‐strand	   breaks	   (DSBs),	   as	   analyzed	   by	   gamma-­‐H2AX	   foci	   formation,	   a	  phenotype	   directly	   related	   to	   dysregulation	   of	   cyclin	   E	   protein.	   Importantly,	   our	  results	  demonstrate	   that	   these	  effects	  are	   likely	   to	  be	  FBW7-­‐dependent,	   as	   cyclin	  E	  degradation	   and	   gamma-­‐H2AX	   foci	   formation	  was	   rescued	   by	   expression	   of	   FBW7	  lacking	  the	  3’UTR.	  	  	  The	   fact	   that	   miR-­‐27a	   is	   a	   negative	   regulator	   of	   FBW7	   and	   is	   overexpressed	   in	  tumors,	  suggest	  that	  it	  may	  act	  as	  a	  novel	  oncogene.	  Interestingly,	  analysis	  of	  miR27a	  expression	   in	   pediatric	   B-­‐ALL,	   a	   tumor	   type	   in	   FBW7	   is	   not	  mutated,	   showed	   that	  miR27	  is	  significantly	  overexpressed	  in	  several	  B-­‐ALL	  subtypes	  compared	  to	  normal	  bone	   marrow	   cells	   and	   CD34+	   B	   cells,	   Additionally,	   in	   hyperdiploid	   pre-­‐B-­‐ALL,	   a	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  this	  happen.	  Unfortunately,	  I	  cannot	  brag	  about	  having	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  people	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  you	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  are	  one	  of	  the	  best	  PhD	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  I’ve	  ever	  met.	  Indeed,	  I	  learnt	  many	  things	  from	  you,	  which	  you	  might	  be	  aware	  of	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  there	  were	  also	  things	  that	  you	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are	  not	  aware	  of.	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  a	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  role	  in	  a	  current	  that	  eventually	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  my	  way	  of	  thinking	  from	  a	  medical	  doctor’s	  perspective	  into	  a	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  and	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  even	  knowing	  it.	  I	  wont	  tell	  you	  how	  though…	  
Nimesh	  Bhaskaran,	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  are	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  man!	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  may	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  what	  I	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  Olle	  in	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  of	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  to	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  know,	  these	  days,	  after	  Salah’s	  statement	  in	  his	  thesis,	  saying	  this	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  people…	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  that	  there	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  is	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  Team”	  with	  me	  and	  indeed	  you	  did	  great	  in	  miR-­‐27a	  project.	  Nice	  job,	  nice	  moments!	  Finally	  thanks	  for	  all	  the	  moments	  that	  I	  seriously	  and	  dedicatedly	  spoke	  Swedish	  and	  you	  kindly	  answered	  in	  English.	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  and	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  Azadeh	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  lovely	  cakes,	  Natalie	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Sjöberg	  and	  Karim.	  	  All	  other	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  and	  present	  members	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  Danne’s	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Martin	  Corcoran,	  it	  was	  a	  great	  pleasure	  to	  have	  you	  around;	  you	  are	  definitely	  that	  kind	  of	  a	  person	  that	  makes	  life	  more	  endurable.	  Your	  are	  a	  great	  scientist	  and	  I	  indeed	  admire	  your	  great	  bioinformatics	  skills	  as	  well	  as	  the	  number	  of	  the	  primer	  pairs	  that	  you	  have	  in	  those	  three	  freezers.	  	  
Katja	  Pokrovskaja,	  you	  are	  immensely	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  with	  a	  heart	  made	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  pure	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  You	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  a	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  that	  any	  lab	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  otherwise	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  become	  a	  big	  mess.	  	  
Lotte,	  thank	  you	  for	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  duper	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  smiling	  all	  the	  time	  and	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  technical	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  during	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  years,	  Linn	  and	  Marianne,	  you	  are	  certainly	  the	  most	  adorable	  living	  female	  scientists,	  Marianne!	  I	  think	  so	  despite	  you	  didn’t	  let	  me	  finish	  my	  lecture	  in	  CCK	  kick	  off,	  Farhad	  you	  are	  a	  nice	  friend,	  thanks	  indeed	  for	  accepting	  to	  come	  to	  my	  defense,	  thanks	  for	  all	  lunch	  chats	  and	  thanks	  for	  all	  pleasant	  discussions	  about	  Persian	  poem	  and	  literature,	  Aris	  and	  Pedram	  for	  being	  so	  nice	  friends	  and	  particularly	  for	  all	  the	  help	  and	  supports	  during	  FACS	  optimization,	  Masako,	  Japan's	  earthquake/tsunami	  was	  so	  sad	  but	  I	  wish	  you	  a	  happy	  future	  and	  good	  luck	  with	  your	  defense	  as	  well,	  Eva	  
B	  and	  Edward.	  
Stefan	  Einhorn,	  I	  would	  like	  to	  convey	  my	  regards	  to	  you,	  most	  likely	  my	  scientific	  career	  endpoint	  will	  resemble	  yours.	  I	  think	  that	  it	  is	  inevitable	  fate	  of	  scientists	  who	  are	  in	  love	  with	  both	  science	  and	  philosophy.	  	  
  46 
	  All	  the	  past	  and	  present	  members	  of	  the	  third	  floor,	  especially:	  Markus,	  I	  never	  figured	  out	  how	  you	  can	  be	  smiling	  everyday	  and	  also	  for	  chats	  in	  Swedish,	  Jacob,	  we	  never	  managed	  to	  bike	  to	  CCK,	  Mahdi,	  you	  are	  a	  component	  of	  an	  amazing	  triad,	  You,	  Salah	  and	  Nimesh.	  I	  never	  laughed	  that	  much	  I	  did	  in	  CCK	  party	  2009,	  it	  was	  not	  less	  during	  our	  lunch	  times	  though,	  Arne	  Östman,	  most	  handsome	  professor	  ever	  seen,	  Reiner,	  
Katarina,	  Marcela,	  Tao,	  Karin	  Aase,	  Mira,	  Elisabeth,	  Åsa,	  Christina,	  Mimmi,	  Lars	  
Holmgren,	  Tanya,	  Malihe,	  Jeroen,	  Maja	  and	  Martin.	  
	  All	  the	  other	  great	  people	  at	  CCK,	  in	  particular:	  
Salah,	  Sorry	  buddy,	  but	  insulting	  me	  for	  being	  in	  love	  with	  “cake”	  is	  not	  such	  a	  big	  mystery	  anymore.	  You	  could	  point	  out	  other	  things…	  ,	  Anna	  V	  for	  great	  OPUSs,	  Erik	  even	  though	  a	  short	  time,	  still	  a	  lot	  of	  joys	  and	  nice	  chats	  during	  your	  stay	  here,	  Amir,	  thank	  you	  for	  all	  planning	  and	  travel	  information	  during	  these	  years,	  I	  wish	  you	  all	  the	  best	  with	  your	  little	  one	  and	  also	  with	  your	  defense,	  Elham,	  Parviz,	  Mohammad,	  Ali,	  
Kambiz,	  Ruby,	  Rona,	  Tomadher,	  Pär,	  Pádraig,	  Wessen,	  Bertha,	  Klas	  Wiman,	  
Kristina,	  Eva	  M,	  Fredrik,	  Anki,	  Andrea,	  Karin,	  Anna	  DG,	  Stig	  Linder,	  Maria	  B,	  
Maria	  H,	  Linn	  and	  Margaretha	  ,	  I	  can	  not	  imagine	  the	  4th	  floor	  without	  you	  two.	  I	  would	  like	  to	  express	  my	  gratitude	  to	  all	  people	  at	  CCK	  that	  make	  everything	  up	  and	  running:	  
Sören	  Lindén,	  you	  are	  one	  of	  the	  nicest	  person	  I	  have	  ever	  seen,	  apart	  from	  your	  great	  intelligence	  to	  solve	  all	  kinds	  of	  problems,	  Eva-­Lena	  Toikka,	  Ann-­Gitt	  Mattsson,	  
Elisabeth	  Djuph,	  Elle	  Tisäter,	  Emily	  Bydén,	  Juan	  Castro	  and	  Barbro	  Larsson.	  
Tina	  Dalianis,	  the	  chairman	  of	  the	  department	  during	  my	  PhD,	  for	  making	  CCK	  such	  a	  creative	  and	  friendly	  research	  environment.	  	  	  All	  the	  collaborators	  that	  made	  the	  projects	  possible	  and	  so	  much	  easier:	  
Mohsen	  Karimi,	  Aris	  pantechoracis,	  Per	  Sangfelt,	  Helena	  Karlström,,	  Galina	  
Selivanova,	  Charles	  Spruck,	  Steve	  Reed,	  Martin	  Widschwendter,	  Jonas	  Bergh,	  
Linda	  Lindström,	  Johanna	  Smed,	  and	  Omid	  Beiki.	  	  All	  the	  collaborators	  and	  friends	  in	  our	  new	  place,	  CMB:	  
Tersa	  and	  Xavier,	  the	  most	  lovely	  scientist	  couple	  I‘ve	  ever	  met,	  thank	  you	  indeed	  for	  your	  great	  help	  and	  assistance	  during	  FACS	  optimization,	  Ayeshe,	  it’s	  great	  to	  have	  a	  colleague	  who	  is	  native	  in	  both	  English	  and	  Swedish,	  Obviously,	  thanks	  a	  lot	  for	  your	  great	  help	  with	  proofreading	  of	  this	  part	  and	  also	  helping	  me	  in	  my	  Swedish	  homeworks!	  You	  are	  also	  unique	  as	  a	  person	  with	  Persian	  origin	  who	  doesn’t	  know	  even	  one	  word	  in	  Persian!,	  Matti,	  for	  your	  sense	  of	  humor	  and	  being	  nice,	  	  
Hamid	  Darban,	  Omid	  Faridani,	  Siamak	  Akbari,	  Raju,	  Nanaho,	  Ales,	  Piergiorgio	  
and	  Örjan	  Wrange	  lab,	  Camilla	  Sjögren,	  Lena	  Stöm,	  Zdravko,	  Irrene	  and	  finally	  
Christer	  Höög,	  the	  chairman	  of	  the	  department.	  
	  
Professor	  Per	  Hellström,	  you	  were	  the	  one	  who	  brought	  me	  to	  Sweden,	  I	  would	  like	  to	  express	  all	  my	  gratitude,	  what	  you	  did	  was	  more	  than	  a	  favor,	  you	  changed	  my	  life	  and	  helped	  my	  dreams	  come	  true.	  Shirin	  and	  I	  never	  forgot	  your	  hospitality	  when	  we	  arrived	  to	  Sweden	  and	  since	  then.	  
Professor	  Zali	  MR,	  I	  need	  to	  thank	  you	  for	  providing	  me	  the	  possibility	  to	  collaborate	  with	  KI	  and	  all	  your	  help	  and	  support.	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  I	  offer	  my	  sincere	  apology	  to	  all	  those	  wonderful	  people	  that	  I	  might	  have	  missed	  to	  mention	  but	  I	  will	  always	  be	  indebted	  to	  you	  for	  helping	  me	  to	  finish	  this	  job.	  	  My	  friends	  from	  outside	  the	  lab:	  the	  three	  musketeers,	  	  
Dr.	  Shahab	  Fatemi,	  you	  have	  been	  my	  best	  friend	  for	  23	  years.	  I	  appreciate	  all	  those	  scientific/philosophical	  chats	  in	  high	  school	  that	  initiated	  my	  appetite	  to	  resolve	  mysteries.	  I	  am	  incredibly	  indebted	  to	  you.	  	  
Dr.	  Shahriar	  Anvari,	  you	  were	  my	  first	  roommate	  in	  my	  entire	  life	  and	  one	  of	  three	  best	  friends	  during	  our	  medical	  studies.	  We	  spent	  days	  and	  nights	  together	  studying	  all	  those	  heavy	  medical	  books	  and	  still	  we	  got	  the	  lowest	  grades.	  
Dr.	  Arash	  Babapour,	  for	  all	  the	  time	  that	  we	  spent	  in	  our	  small	  dorm	  with	  Shahriar,	  we	  laughed	  at	  small	  things	  just	  to	  forget	  the	  hardship	  of	  being	  so	  far	  from	  our	  families.	  Finally,	  I	  have	  never	  met	  such	  an	  intelligent	  person	  who	  prepares	  the	  least	  and	  gains	  the	  highest	  grades.	  	  Lastly	  my	  family	  members:	  My	  grandmas	  and	  grandpas,	  Behjat,	  Batool,	  Abbas	  and	  Baba	  Zandian,	  for	  all	  the	  love	  that	  you	  gave	  me	  when	  you	  were	  still	  alive.	  My	  father	  and	  mother	  in	  law,	  Ebrahim	  Zabihi	  and	  Manijeh	  Kamali	  for	  being	  extremely	  nice	  and	  understanding	  and	  for	  giving	  me	  an	  angel	  to	  share	  my	  life	  with.	  	  	  
Dr.	  Nooshin,	  congratulations	  again	  for	  your	  graduation,	  you	  did	  great,	  no	  one	  could	  put	  as	  much	  force	  as	  you	  did,	  Vahid,	  my	  dear	  brother	  in	  law,	  you	  have	  a	  golden	  heart	  and	  that	  makes	  you	  to	  buy	  presents	  for	  the	  whole	  family	  each	  new	  year!	  Wish	  you	  all	  the	  best	  in	  your	  shiny	  future.	  	  My	  mother,	  Farah,	  you	  were	  the	  first	  one	  in	  so	  many	  things	  in	  my	  life,	  the	  first	  one	  who	  gave	  me	  life,	  the	  first	  one	  who	  loved	  me,	  the	  first	  one	  who	  fed	  me,	  the	  first	  who	  taught	  me,	  the	  first	  one	  who	  everything.	  Thank	  you	  from	  the	  bottom	  of	  my	  heart	  maman!	  My	  father,	  Mohammad,	  you	  are	  my	  legendary	  hero.	  You	  took	  care	  of	  me,	  most	  of	  the	  time	  invisibly,	  and	  always	  encouraged	  me	  and	  made	  me	  not	  forget	  to	  follow	  my	  scientific	  dreams.	  Thank	  you	  for	  everything!	  	  My	  dearest	  brother	  and	  music	  collaborator,	  Sina,	  you	  are	  more	  than	  nice,	  I	  wish	  you	  all	  the	  best	  in	  your	  future	  life,	  my	  lovely	  sister	  Sheida,	  thanks	  for	  always	  being	  my	  main	  driving	  force	  to	  proceed.	  You	  are	  passionate	  and	  wise	  at	  the	  same	  time,	  which	  makes	  you	  stronger	  to	  go	  ahead.	  Guys!,	  I	  offer	  my	  apologies	  if	  I	  have	  not	  been	  the	  best	  brother	  always.	  I	  left	  home	  when	  you	  were	  small	  kids	  and	  did	  not	  have	  a	  chance	  to	  be	  around	  a	  lot.	  Thank	  you	  for	  everything!	  	  My	  dear	  uncle,	  Dr.	  Ali	  Akhoondi,	  you	  were	  the	  person	  who	  inspired	  me	  to	  become	  a	  doctor.	  I	  used	  to	  mimic	  what	  you	  did	  in	  your	  office	  and	  my	  favorite	  game	  during	  my	  childhood	  was	  treating	  my	  imaginary	  patients.	  I	  admire	  your	  great	  soul.	  	  
Atrin,	  my	  dear	  smart	  and	  naughty	  son.	  I	  am	  sorry	  for	  making	  you	  sit	  still	  during	  these	  years	  (unsuccessfully)	  especially	  these	  days	  while	  I	  am	  writing	  my	  thesis.	  	  I	  am	  sure	  you	  feel	  by	  all	  means	  that	  having	  father	  defending	  his	  PhD	  thesis	  is	  not	  fun	  at	  all,	  right?	  I	  promise	  to	  make	  it	  up	  to	  you,	  Jag	  lovar…	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Shirin,	  if	  there	  are	  angels	  on	  earth	  you	  are	  one	  of	  a	  kind!	  I	  am	  deeply	  grateful	  that	  you	  never	  complained	  during	  these	  tough	  years	  and	  tolerated	  me	  when	  I	  was	  shockingly	  annoying.	  When	  my	  experiments	  failed	  you	  brought	  me	  calm	  and	  relaxation	  with	  your	  heavenly	  love	  –	  a	  pillar	  to	  lean	  on.	  I	  will	  never	  forget	  all	  the	  moments	  you	  encouraged	  my	  ambitions,	  which	  made	  me	  sure	  I	  was	  stepping	  in	  the	  right	  direction.	  	  I	  have	  been	  incredibly	  fortunate	  to	  share	  my	  life	  with	  you.	  
You're	  my	  everlasting	  love.	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